8-K
Enovis CORP false 0001420800 0001420800 2023-10-19 2023-10-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 19, 2023

 

 

Enovis Corporation

(Exact name of registrant as specified in its charter)

 

 

Commission File Number: 001-34045

 

Delaware   001-34045   54-1887631

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2711 Centerville Road, Suite 400

Wilmington, DE

  19808
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (302) 252-9160

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to 12(b) of the Act:

 

Title of Each Class

 

Trading
Symbols

 

Name of Each Exchange
on Which Registered

Common Stock, par value $0.001 per share   ENOV   New York Stock Exchange

 

 

 


Item 2.02.

Results of Operations and Financial Condition.

On October 19, 2023, Enovis Corporation (the “Company”) released the following preliminary information about its performance for the third quarter ended September 29, 2023.

Revenues for the three months ended September 29, 2023 are expected to be between $414 and $418 million, compared to approximately $383 million for the three months ended September 30, 2022, representing an increase of approximately 8 to 9%.

Adjusted EBITDA for the three months ended September 29, 2023 is expected to be between $64 and $66 million, compared to approximately $57 million for the three months ended September 30, 2022, representing an increase of approximately 12 to 15%.

The foregoing preliminary financial estimates reflect management’s current views and may change as a result of management’s review of results and other factors, including a wide variety of significant business, economic and competitive risks and uncertainties. Such preliminary financial information is subject to the finalization and closing of the accounting books and records of the Company (which have yet to be performed) and should not be viewed as a substitute for full quarterly financial statements prepared in accordance with U.S. GAAP. In the course of preparing and finalizing the financial statements for the three months ended September 29, 2023, the preliminary estimates for the three months ended September 29, 2023 will be subject to change and the Company may identify items that will require it to make adjustments to the Company’s preliminary estimates described above. Any such changes could be material. For these or other reasons, the preliminary financial estimates for the three months ended September 29, 2023 may not ultimately be indicative of the Company’s results for such periods and actual results may differ materially from those described above. No independent registered public accounting firm has audited, reviewed or compiled, examined or performed any procedures with respect to these preliminary results, nor have they expressed any opinion or any other form of assurance on these preliminary estimated results.

Adjusted EBITDA is not prepared in accordance with U.S. GAAP and is included in this Current Report on Form 8-K because it is used by the Company’s management to assess its operating performance. The table below provides a reconciliation of preliminary adjusted EBITDA to the closest comparable U.S. GAAP financial measure, net income (loss) from continuing operations, for the three months ended September 29, 2023.

Adjusted EBITDA represents net income or loss from continuing operations excluding taxes, depreciation and amortization, stock-based compensation costs and restructuring and other charges, European Union Medical Device Regulation and other costs, strategic transaction costs, insurance settlement (gain) loss, and inventory step up costs. Adjusted EBITDA should not be considered in isolation from, or as a substitute for, net income (loss) from continuing operations or other measures calculated in accordance with U.S. GAAP.

 

Dollars in millions

(Unaudited)

 
     Three Months Ended September 29, 2023  
       Low(1)                 High(2)    

Net Income (Loss) from continuing operations (GAAP)

   $ (20.1       $ (19.4

Income tax benefit

     (6.0         (6.2

Other Income

        (0.8   

Interest expense, net

        5.8     
  

 

 

       

 

 

 

Operating loss (GAAP)

     (21.1         (20.6

Adjusted to Add:

        

Restructuring and other charges

     5.1           5.6  

Medical Device Regulation (MDR) and other costs(3)

     6.0           6.5  

Strategic transaction costs(4)

     10.3           10.8  

Stock-based compensation

        8.4     

Depreciation and other amortization

        21.5     

Amortization of acquired intangibles

        34.0     

Inventory step-up

        —      
  

 

 

       

 

 

 

Adjusted EBITDA

   $ 64.0         $ 66.0  
  

 

 

       

 

 

 

 

(1)

Assumes a GAAP tax rate of 23%.

(2)

Assumes a GAAP tax rate of 24.2%.

(3)

Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.

(4)

Strategic transaction costs includes costs related to the Separation from ESAB Corporation and certain transaction and integration costs related to recent acquisitions.

 

Item 7.01

Regulation FD Disclosure.

In this Current Report on Form 8-K, the Company is furnishing the following information of LimaCorporate S.p.A. (the “Lima”), which it plans to provide to certain investors: (i) audited consolidated financial statements of Lima as of and for the year ended December 31, 2022, attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01; (ii) unaudited condensed interim consolidated financial statements of Lima as of and for the six months ended June 30, 2023, attached hereto as Exhibit 99.2 and incorporated by reference in this Item 7.01; and (iii) preliminary unaudited pro forma condensed combined financial statements of the Company and Lima as of and for the six months ended June 30, 2023 and for the year ended December 31, 2022, in each case, that give effect to the Company’s planned acquisition of Lima, attached hereto as Exhibit 99.3 and incorporated by reference in this Item 7.01.

The Company cautions that Lima’s financial statements have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board and, to the extent audited, have been audited in accordance with International Auditing Standards. These standards differ from generally accepted accounting principles in the United States and the auditing standards promulgated by the PCAOB and American Institute of Certified Public Accountants. The Lima financial statements were not audited or reviewed in accordance with generally accepted accounting standards in the United States or the auditing standards promulgated by the PCAOB and American Institute of Certified Public Accountants. As a result, the pro forma financial information does not comply with Article 11 of Regulation S-X under the Securities Act of 1933, as amended (the “Securities Act”). You should not place undue reliance on such financial statements or on the pro forma financial statements that rely on such financial statements.

The information in this report (including the exhibits) furnished pursuant to Item 7.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in the report that is required to be disclosed solely by Regulation FD. Furthermore, the information provided in Exhibits 99.1, 99.2 and 99.3 shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act, unless such incorporation by reference is specifically referenced therein.

 

Item 8.01

Other Events

On October 19, 2023, the Company issued a press release announcing its intention to offer convertible senior notes due 2028 (the “Notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The Company also expects to grant the initial purchasers of the Notes an option to purchase additional Notes within a 13-day period beginning on, and including, the initial closing date. A copy of the press release is attached hereto as Exhibit 99.4 and is incorporated herein by reference.

This Current Report on Form 8-K does not constitute an offer to purchase securities or a solicitation of an offer to sell any securities or an offer to sell or the solicitation of an offer to purchase any securities nor does it constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is unlawful.


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

  

Description

99.1    Audited Consolidated Financial Statements of Lima as of and for the year ended December 31, 2022.
99.2    Unaudited Condensed Consolidated Interim Financial Statements of Lima as of and for the six months ended June 30, 2023.
99.3    Preliminary Unaudited Pro Forma Condensed Combined Financial Statements of the Company and Lima as of and for the Six Months ended June 30, 2023 and for the year ended December 31, 2022.
99.4    Press Release dated October 19, 2023.
104    Cover Page Interactive Data File, formatted in Inline XBRL, and included as Exhibit 101.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 19, 2023   ENOVIS CORPORATION
    By:  

/s/ Phillip B. Berry

    Name:   Phillip B. Berry
    Title:  

Senior Vice President

and Chief Financial Officer

EX-99.1

Exhibit 99.1

 

LOGO

KPMG S.p.A.

Revisione e organizzazione contabile

Piazza Salvemini, 20

35131 PADOVA PD

Telefono +39 049 8249101

Email it-fmauditaly@kpmg.it

PEC kpmgspa@pec.kpmg.it

Independent auditors’ report

To the board of directors of

Limacorporate S.p.A.

Report on the audit of the consolidated financial statements

Opinion

We have audited the accompanying consolidated financial statements of the Limacorporate Group (the “group”), which comprise the statement of financial position as at 31 December 2022, the income statement and statements of comprehensive income, cash flows and changes in equity for the year then ended and notes thereto, which include a summary of the significant accounting policies.

In our opinion, the accompanying consolidated financial statements give a true and fair view of the financial position of the Limacorporate Group as at 31 December 2022 and of its financial performance and cash flows for the year then ended in accordance with the International Financial Reporting Standards issued by International Accounting Standards Board (“IFRS issued by the IASB”).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISA). Our responsibilities under those standards are further described in the “Auditors’ responsibilities for the audit of the consolidated financial statements” section of our report. We are independent of Limacorporate S.p.A. (the “parent”) in accordance with the ethics and independence rules and standards applicable in Italy to audits of financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter – IFRS issued by the IASB adoption and error correction

We draw attention to Note 4.1 “Transition to IFRS issued by IASB“ to the consolidated financial statements, which indicates the group has corrected an error related to the payback mechanism accounted in compliance with IFRS 15 that was reported prior to the group’s adoption of the IFRS issued by IASB. Our opinion is not modified in respect of this matter.

Other Matter

The consolidated financial statements of Limacorporate Group as at 31 December 2022 has been prepared for its inclusion in the offering memorandum drawn up by Enovis Corporation as part of its potential issue of notes.

 

 

 

KPMG S.p.A. è una società per azioni di diritto italiano e fa parte del

network KPMG di entità indipendenti affiliate a KPMG International

Limited, società di diritto inglese.

  

Ancona Bari Bergamo Bologna Bolzano Brescia

Catania Como Firenze Genova

Lecce Milano Napoli Novara Padova Palermo Parma Perugia  

Pescara Roma Torino Treviso

Trieste Varese Verona

  

Società per azioni

Capitale sociale

Euro 10.415.500,00 i.v.

Registro Imprese Milano Monza Brianza Lodi    

e Codice Fiscale N. 00709600159

R.E.A. Milano N. 512867

Partita IVA 00709600159

VAT number IT00709600159

Sede legale: Via Vittor Pisani, 25

20124 Milano MI ITALIA


LOGO

Limacorporate Group

Independent auditors’ report

31 December 2022

 

Responsibilities of the parent’s directors and board of statutory auditors (“Collegio Sindacale”) for the consolidated financial statements

The directors are responsible for the preparation of consolidated financial statements that give a true and fair view in accordance with the International Financial Reporting Standards issued by International Accounting Standards Board and, within the terms established by the Italian law, for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

The directors are responsible for assessing the group’s ability to continue as a going concern and for the appropriate use of the going concern basis in the preparation of the consolidated financial statements and for the adequacy of the related disclosures. The use of this basis of accounting is appropriate unless the directors believe that the conditions for liquidating the parent or ceasing operations exist, or have no realistic alternative but to do so.

The Collegio Sindacale is responsible for overseeing, within the terms established by the Italian law, the group’s financial reporting process.

Auditors’ responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISA will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with ISA, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

 

 

identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;

 

 

obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the group’s internal control;

 

 

evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors;

 

 

conclude on the appropriateness of the directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors’ report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors’ report. However, future events or conditions may cause the group to cease to continue as a going concern;

 

2


LOGO

Limacorporate Group

Independent auditors’ report

31 December 2022

 

 

evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation;

 

 

obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance, identified at the appropriate level required by ISA, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Padua, 5 October 2023

KPMG S.p.A.

 

LOGO

Silvia Di Francesco

Director

 

3


LOGO

Consolidated financial statements as at 31 December 2022

 

LOGO


Contents

 

Consolidated financial statements as at 31 December 2022

  

Consolidated financial statements as at 31 December 2022 of the Limacorporate Group

     6  

Notes to the consolidated financial statements as at 31 December 2022

     11  

Other information

     51  

 

5


Consolidated financial statements as at 31 December 2022 of the Limacorporate Group

Statement of financial position

 

(€‘000)

                        

ASSETS

   Note     31/12/2022     31/12/2021     01/01/2021  

Non-current assets

        

Other intangible assets

     [3.1     58,234       53,595       44,477  

Goodwill

     [3.2     384,216       398,305       396,900  

Property, plant and equipment

     [3.3     79,837       81,773       85,288  

Equity investments

     [3.4     2       2       402  

Deferred tax assets

     [3.5     31,709       33,462       31,895  

Other non-current assets

     [3.6     861       705       663  
    

 

 

   

 

 

   

 

 

 

Total non-current assets

       554,859       567,843       559,625  
    

 

 

   

 

 

   

 

 

 

Current assets

        

Inventories

     [3.7     86,728       87,421       84,166  

Trade receivables

     [3.8     70,161       66,891       63,070  

Current tax assets

     [3.9     2,087       2,554       4,361  

Other current assets

     [3.10     14,192       11,247       11,469  

Cash and cash equivalents

     [3.11     25,920       21,503       26,273  
    

 

 

   

 

 

   

 

 

 

Total current assets

       199,088       189,617       189,340  
    

 

 

   

 

 

   

 

 

 

TOTAL ASSETS

       753,947       757,461       748,965  
    

 

 

   

 

 

   

 

 

 

EQUITY AND LIABILITIES

        

Equity

        

Share capital

     [3.12     9,868       9,868       9,868  

Share premium reserve

     [3.12     14,425       14,425       14,425  

Other reserves

     [3.12     323,510       317,570       310,762  

Retained earnings (accumulated deficit)

     [3.12     (21,966     (18,862     (6,380

Profit (loss) for the year

     [3.12     (19,273     (2,539     (12,482
    

 

 

   

 

 

   

 

 

 

Total equity attributable to the owners of the parent

       306,564       320,463       316,194  
    

 

 

   

 

 

   

 

 

 

Total equity

       306,564       320,463       316,194  
    

 

 

   

 

 

   

 

 

 

Non-current liabilities

        

Non-current financial liabilities

     [3.15     10,165       283,573       287,407  

Employee benefits

     [3.14     1,296       1,442       1,421  

Deferred tax liabilities

     [3.5     19,275       17,296       12,986  

Provisions for risks and charges

     [3.13     17,156       15,314       12,847  

Other non-current liabilities

     [3.16     649       5,250       5,476  
    

 

 

   

 

 

   

 

 

 

Total non-current liabilities

       48,541       322,875       320,137  
    

 

 

   

 

 

   

 

 

 

Current liabilities

        

Current financial liabilities

     [3.15     336,659       61,536       61,156  

Trade payables

     [3.17     36,564       32,343       28,941  

Current tax liabilities

     [3.18     877       202       491  

Other current liabilities

     [3.19     24,742       20,041       22,047  
    

 

 

   

 

 

   

 

 

 

Total current liabilities

       398,842       114,123       112,635  
    

 

 

   

 

 

   

 

 

 

TOTAL EQUITY AND LIABILITIES

       753,947       757,461       748,965  
    

 

 

   

 

 

   

 

 

 

 

6


Income statement

 

(€‘000)

                  
     Note     2022     2021  

Revenue

     [3.20     245,669       210,543  

Other revenues and income

     [3.20     5,798       3,973  
    

 

 

   

 

 

 

Total revenue and income

       251,467       214,517  
    

 

 

   

 

 

 

Raw materials, consumables, supplies and goods

     [3.21     (56,391     (53,530

Services

     [3.22     (81,645     (69,910

Change in w.i.p., semi-finished products and finished goods

     [3.23     (887     2,058  

Personnel expenses

     [3.24     (76,858     (60,773

Amortisation and Depreciation

     [3.25     (35,408     (32,517

Impairment losses on trade receivables

     [3.25     (502     (429

Impairment losses on fixed assets

     [3.25     (16,152     (209

Other operating costs

     [3.26     (1,857     (1,509

Internal work capitalised

     [3.27     13,532       16,250  
    

 

 

   

 

 

 

Operating costs

       (256,167     (200,570
    

 

 

   

 

 

 

Operating profit

       (4,700     13,947  
    

 

 

   

 

 

 

Financial income

     [3.28     14,561       7,829  

Financial expense

     [3.28     (22,609     (20,785
    

 

 

   

 

 

 

Net financial expense

       (8,048     (12,956
    

 

 

   

 

 

 

Pre-tax income (loss)

       (12,748     991  
    

 

 

   

 

 

 

Income tax benefit (expense)

     [3.29     (6,526     (3,529
    

 

 

   

 

 

 

Profit (loss) for the year

       (19,273     (2,539
    

 

 

   

 

 

 

of which attributable to the owners of the parent

       (19,273     (2,539
    

 

 

   

 

 

 

 

7


Statement of comprehensive income

 

(€‘000)

                  
     Note     2022     2021  

Profit (loss) for the year

       (19,273     (2,539
    

 

 

   

 

 

 

Other comprehensive income (expense)

      

Items that will never be reclassified to profit or loss (A)

      

Remeasurements of the net defined benefit liability (asset)

     [3.14     71       3  

Related tax

     [3.14     (17     (1
    

 

 

   

 

 

 
       54       2  
    

 

 

   

 

 

 

Items that are or may be reclassified to profit or loss (B)

      

Exchange differences on translation of foreign operations

     [3.12     871       1,842  
    

 

 

   

 

 

 
       871       1,842  
    

 

 

   

 

 

 

Other comprehensive income (expense), net of tax (A+B)

       925       1,844  
    

 

 

   

 

 

 

Comprehensive income (expense) for the year

       (18,348     (695
    

 

 

   

 

 

 

Comprehensive income (expense) attributable to:

      

Owners of the parent

       (18,348     (695
    

 

 

   

 

 

 

 

8


Statement of changes in equity

 

(€‘000)

                                                                       
    Note     Share
capital
    Share
premium
reserve
    Legal
reserve
    Merger
reserve
    Equity
Injections
    Translation
reserve
    Actuarial
reserve
    Other
reserves
    Retained earnings
including Profit (loss)
for the year
    Total equity
attributable to
the owners of
the parent
    Total equity  

At 1 January 2021

      9,868       14,425       2,101       288,261       23,088       (334     (25     (2,328     (18,862     316,194       316,194  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Statement of comprehensive income

                       

Profit for the year

    [3.12     —        —        —        —        —        —        —        —        (2,539     (2,539     (2,539

Other comprehensive income

    [3.12     —        —        —        —        —        1,842       2       —        —        1,844       1,844  

Comprehensive income

      —        —        —        —        —        1,842       2       —        (2,539     (694     (694

Owner transactions

                       

Allocation of the loss for the previous year

    [3.12     —        —        —        —        —        —        —        —        —        —        —   

Other owner transactions

    [3.12     —        —        —        —        4,963       —        —          —        4,963       4,963  

Total owner transactions

      —        —        —        —        4,963       —        —        —        —        4,963       4,963  

Other changes

    [3.12     —        —        —        —        —        —        —        —        —        —        —   
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 31 December 2021

      9,868       14,425       2,101       288,261       28,051       1,508       (23     (2,328     (21,401     320,463       320,463  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Statement of comprehensive income

                       

Profit for the year

    [3.12     —        —        —        —        —        —        —        —        (19,273     (19,273     (19,273

Other comprehensive income

    [3.12     —        —        —        —        —        871       54       —        —        925       925  

Comprehensive income

      —        —        —        —        —        871       54       —        (19,273     (18,349     (18,349

Owner transactions

                       

Allocation of the loss for the previous year

    [3.12     —        —        —        —        —        —        —        565       (565     —        —   

Other owner transactions

    [3.12     —        —        —        —        —        —        —          —        —        —   

Total owner transactions

      —        —        —        —        —        —        —        565       (565     —        —   

Other changes

    [3.12     —        —        —        —        —        —        —        4,450       —        4,450       4,450  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 31 December 2022

      9,868       14,425       2,101       288,261       28,051       2,379       31       2,687       (41,239     306,564       306,564  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

9


Statement of cash flows

 

(€‘000)

                  
     Note     2022     2021  

Operating activities

      

Profit (loss) for the year

     [3.12]       (19,273     (2,539

Income tax (benefit)/expense

     [3.29]       6,526       3,529  

Net financial (income)/expense

     [3.28]       10,809       13,979  

Amortisation, depreciation and impairment losses

     [3.25]       50,649       32,726  

Accruals/(Release) to provisions

     [3.26]       1,842       3,204  

Net (gains)/loss on disposals

     [3.20] [3.26]       (629     (550

FX on contingent consideration

     [3.28]       1,031       1,384  

Cash flows from operating activities before changes in working capital

       50,955       51,734  

Change in inventories

     [3.7]       693       (3,255

Change in trade receivables

     [3.8]       (3,270     (3,502

Change in trade payables

     [3.17]       4,220       3,402  

Change in other assets/liabilities

     [3.10] [3.16] [3.19]       316       523  

Change in non-current assets

     [3.6]       (156     358  

Income taxes paid

       (2,019     (846
    

 

 

   

 

 

 

Cash flows from operating activities A)

       50,739       48,414  
    

 

 

   

 

 

 

Investing activities

      

Acquisitions of property, plant and equipment

     [3.3]       (25,234     (21,983

Disposal of property, plant and equipment

     [3.3]       1,418       2,108  

Acquisitions of intangible assets

     [3.1]       (12,229     (14,229

Disposal of intangible assets

     [3.1]       955       47  
    

 

 

   

 

 

 

Cash flows used in investing activities B)

       (35,090     (34,056
    

 

 

   

 

 

 

Financing activities

      

Third party funds

      

Net change in current financial liabilities

     [3.15]       8,916       805  

Gross change in non-current financial liabilities

     [3.15]       (0     (572

Decrease in lease liabilities

     [3.15]       (4,401     (3,384

Net interest income

     [3.28]       163       154  

Net interest paid

     [3.28]       (15,911     (16,131
    

 

 

   

 

 

 

Cash flows from (used in) in financing activities C)

       (11,231     (19,127
    

 

 

   

 

 

 

Increase (decrease) in liquid funds (A ± B ± C)

       4,417       (4,770
    

 

 

   

 

 

 

Opening cash and cash equivalent

       21,503       26,273  

Closing cash and cash equivalent

       25,920       21,503  
    

 

 

   

 

 

 

Increase (decrease) in cash and cash equivalents

       4,417       (4,770
    

 

 

   

 

 

 

 

10


Notes to the consolidated financial statements as at 31 December 2022

[2.1] General information

The Limacorporate Group (the “group”) designs, creates and sells joint implants and repair solutions in the medical sector.

The parent, Limacorporate S.p.A. (“Limacorporate” or the “parent”), was set up and is domiciled in Italy. Its registered office is at Via Nazionale 52, San Daniele del Friuli (Udine) and its company registration number is 173824.

The group carries out most of its business at its registered office while some activities are also performed by the subsidiaries.

The consolidated financial statements as at and for the year ended 31 December 2022 include the financial statements of the parent and the subsidiaries (together the “group”).

These consolidated financial statements as at 31 December 2022 were approved by the parent’s board of directors at its meeting on 3 October 2023.

The parent is managed and coordinated by Emil Holding II S.à.r.l., whose details are provided below:

 

   

Registered office: 26A, Boulevard Royal, L-2449 Luxembourg.

 

   

Legal form: limited liability company.

 

   

Description of its business activities and main operations: holding company

 

   

Ultimate parent’s name: Emil NewCo S.à.r.l.

 

   

Name of the ultimate indirect parent: EQT Luxembourg Management S.à r.l.

[2.2] Basis of presentation

The consolidated financial statements as at 31 December 2022 is prepared in accordance with the IFRS issued by International Accounting Standards Board (IASB) applying IFRS 1 – First-time Adoption of International Financial Reporting Standards.

Following the adoption of the IFRS issued by IASB, the Group’s equity and profit for the year previously determined under the IFRS endorsed by the European Union, were corrected due to a correction of error related to the payback mechanism accounted in compliance with IFRS 15, retrospectively, as reduction of revenue (variable consideration). The note [4.1] Transition to IFRS issued by IASB describes the corrected error and transition criteria and includes the reconciliation schedules of the Group’s equity and profit for the year for the comparative periods.

These consolidated financial statements as at 31 December 2022 comprise the statement of financial position, income statement, statement of comprehensive income, statement of changes in equity, statement of cash flows and these notes. They comply with the provisions of IAS 1 Presentation of financial statements and the general principle of historical cost, except for those items that, pursuant to the IFRS, are measured at fair value, as explained in the accounting policies of the individual captions in note 2.4 Basis of preparation. The statement of financial position has been prepared by separating assets and liabilities into current and non-current, whereas costs are classified in the income statements on the basis of their nature. The statement of cash flows has been prepared using the indirect method.

The notes to the consolidated financial statements as at 31 December 2022 include the information generally required by ruling legislation and the IFRS, suitably presented with reference to the financial statements schedules used.

The consolidated financial statements as at 31 December 2022 have been prepared on a going concern basis, as the related assumptions are deemed to be met.

All figures are in thousands of Euros, unless indicated otherwise. The Euro is the parent’s functional and presentation currency. For each financial statements caption, the corresponding amount of the previous year is provided for comparative purposes.

 

11


The consolidated financial statements of Limacorporate Group as at 31 December 2022 has been prepared for its inclusion in the offering memorandum drawn up by Enovis Corporation as part of its potential issue of notes.

[2.3] Consolidation scope

The consolidated financial statements of the Limacorporate Group as at 31 December 2022 include the financial statements of the parent and the Italian and foreign subsidiaries at 31 December 2022.

Subsidiaries are those companies over which the group has control, as defined by IFRS 10 Consolidated financial statements as at 31 December 2022. Control exists when the group has the power to, directly or indirectly, govern the financial and operating policies of an entity so as to obtain benefits from its activities. The financial statements of subsidiaries are included in the consolidated financial statements as at 31 December 2022 starting from when control is assumed and until such control ceases to exist.

The table below lists the companies included in the consolidation scope at 31 December 2022.

Subsidiaries are included in the consolidation scope from when the group acquires control, as defined above, and are excluded from when the group no longer has control.

Amounts in thousands (of the stated currency)

 

   

Registered office

  Currency   Share/quota
capital
    Equity     Profit (Loss)
for the year
    %  

LIMA AUSTRIA GmbH

  Seestadtstrasse 27 Top 6-7, 1220 Vienna (Austria)    (EUR)     35       1,278       172       100

LIMA BELGIUM SRL

  Chaussée de Wavre 504, boîte 5A - 1390 Grez Doiceau (Belgium)   (EUR)     30       -1,250       289       100

LIMA CZ s.r.o.

  Do Zahràdek I., 157/5 - 155 21 Praha 5 - Třebonice - (Czech Republic)   (CZK)     200       116,390       16,178       100

LIMA DENMARK ApS

  Lyngebaekgards Alle 2, 2990 Niva (Denmark)   (DKK)     500       427       142       100

LIMA DEUTSCHLAND GmbH

  Kapstadtring 10, - 22297 Hamburg - (Germany)   (EUR)     25       5,291       1,674       100

LIMA DO BRASIL LTDA

  Al. Campinas, 728 – 2° andar salas 201, 202, 203 e 204.- Jardim Paulista - Sao Paulo - SP - CEP:01404- 001 (Brazil)   (BRL)     1,500       -10,475       7,754       100

LIMA FRANCE Sas

  1, Allée des Alisiers - Immeuble “Le Galilée” - 69500 Bron - (France)   (EUR)     40       440       161       100

LIMA IMPLANTES PORTUGAL S.U. LDA

  Rua Pêro Vaz de Caminha 8 E 2660-441 Stº António Cavaleiros - (Portugal)   (EUR)     5       2,357       125       100

LIMA IMPLANTES Slu

  C/ Manuel Tovar, 33-35 28034 Madrid - (Spain)   (EUR)     200       1,089       29       100

LIMA JAPAN K.K.

  Tokyo Front Terrace 13F 2-3-14 Higashi Shinagawa, Shinagawa, Tokyo, 140-0002 , (Japan)   (JPY)     10,000       -984,102       -34,681       100

LIMA KOREA Co., Ltd

  Zero Building 11th Floor, 14 Teheran Ro 84 Gil, Gangnam Gu, Seoul 06178 - (Korea)   (KRW)     100,000       -1,932,158       299,988       100

LIMA NETHERLANDS B.V.

  Bergweg 153A, 3707AC Zeist - (Netherlands)   (EUR)     18       1,007       232       100

LIMA O.I. d.o.o. - ORTOPEDIJA I IMPLANTATI

  Ante Kovačića, 3 - 10000 Zagreb - (Croatia)   (HRK)     300       32,024       1,586       100

LIMA ORTHOPAEDICS AUSTRALIA Pty Ltd

  Unit 1, 40 Ricketts Road - Mt Waverley, 3149 Victoria - (Australia)   (AUD)     0       21,875       405       100

LIMA ORTHOPAEDICS NEW ZEALAND Pty Ltd

  20 Crummer Rd Grey Lynn 1021 Auckland 1021 - New Zealand   (NZD)     0       10,014       195       100

LIMA ORTHOPAEDICS SOUTH AFRICA (PTY) LTD

  Northlands Deco Park, Stand 326, 10 Newmarket Street, Design Boulevard, Northriding, 2186 (South Africa)   (ZAR)     0       -11,459       -92       100

LIMA ORTHOPAEDICS UK Ltd

  4 Office Village Forder Way Cygnet Park Hampton Peterborough Peterborough PE7 8GX (United Kingdom)   (GBP)     0       6,932       947       100

LIMA POLSKA SP. z.o.o.

  ul. Ul Lopuszanska 95 - 02-457 Warsaw (Poland)   (PLN)     5       472       1,126       100

LIMA SK S.r.o.

  Cesta na Stadiòn 7 - 97404 Banska Banska Bystrica - (Slovakia)   (EUR)     7       6,371       313       100

LIMA SWEDEN AB

  Box 180 - SE-184 22 Akersberga - (Sweden)   (SEK)     100       1,678       666       100

LIMA SWITZERLAND SA

  Birkenstrasse, 49 - 6343 Rotkreuz - Zug - (Switzerland)   (CHF)     100       2,084       328       100

TASFIYE HALINDE LIMA TURKEY ORTOPEDI AS

  Serifali Mah. Hendem Cad.No: 54 Canan Residence OFIS A-2,34775 - UMRANIYE - Istanbul - (Turkiye)   (TRY)     50       -13,713       -11,252       100

LIMA USA Inc.

  2001 NE Green Oaks Blvd, Suite 100 - Arlington, TX 76006 - (United States)   (USD)     20       79,420       -1,368       100

LIMA SM S.p.A. in liquidazione

  Strada Borrana, 38 - Serravalle 47899 - (Repubblica di San Marino)   (EUR)     2,701       4,051       -1,174       100

TechMah Medical LLC

  2099 Thunderhead Road, Suite 302 - Knoxville, TN 37922 - (United States)   (USD)     29,084       961       -8,268       100

LIMA (BEIJING) MEDICAL DEVICES CO., LTD.

  Room 616, 6/F, Building 1, No.1, Lize Zhong 2 Road, Chaoyang District, Beijing, China   (CNY)     3,014       -3,784       -2,761       100

LIMA ORTHOPAEDICS CANADA INC.

  3715 Laird Road Suite Unit 9, Mississauga, ON, Canada   (CAD)     200       221       28       100

 

12


Lima Orthopaedics Canada Inc. incorporated under Canadian law in October 2021 was included in the consolidation scope in 2022. It began operations in the first half of 2022 and was not consolidated in 2021 as it was not yet up and running and was immaterial.

For consolidation purposes, the figures of the individual companies at the reporting date were restated to comply with the IFRS adopted by the group. The reporting date of all of the consolidated companies is 31 December.

The basis of consolidation is set out below:

 

   

Adopting the line-by-line method, showing the portions of equity and profit or loss for the year attributable to non-controlling interests and recognising assets, liabilities, revenue and costs regardless of the percentage held in the subsidiaries.

 

   

Eliminating items deriving from intragroup transactions involving consolidated companies, including any unrealised gains and losses arising from intragroup transactions and recognising the resulting deferred tax effects.

 

   

Eliminating intragroup dividends and reallocating them to opening equity reserves.

 

   

Eliminating the carrying amount of investments in consolidated companies and the relevant portion of equity, allocating the resulting positive and negative differences to the relevant captions (assets, liabilities and equity), as defined at the time of acquisition of the investment and considering any subsequent variations. After control is acquired, any acquisitions of non-controlling interests or sales of shares to non-controlling interests that do not entail loss of control are recognised as owner transactions and the relevant effects are taken directly to equity. Any differences between the change in equity attributable to non-controlling interests and cash and cash equivalents exchanged are recognised under changes in equity attributable to the owners of the parent.

 

   

The financial statements of foreign operations are translated into Euros using the annual average rate for income statement items and the closing rate for statement of financial position items. The difference between the two rates along with the translation differences deriving from changes in opening and closing exchange rates are recognised as changes in equity.

The following rates were applied in translating the financial statements of foreign operations:

 

Currency

   Average Rate      Closing Rate  

AUD - Australian Dollar

     1.51670        1.56930  

BRL - Brazilian Real

     5.43990        5.63860  

CAD - Canadian Dollar

     1.36950        1.44400  

CHF - Swiss Franc

     1.00470        0.98470  

CZK - Czech Koruna

     7.07880        7.35820  

CNY - Yuan Renminbi

     24.56590        24.11600  

DKK - Danish Krone

     7.43960        7.43650  

GBP - Pound Sterling

     0.85276        0.88693  

HRK - Croatian Kuna

     7.53490        7.53650  

JPY - Japanese Yen

     138.0274        140.66  

KRW - South Korean Won

     1,358.07        1,344.09  

NZD - New Zealand Dollar

     1.65820        1.67980  

PLN - Polish Zloty

     4.68610        4.6808  

SEK - Swedish Krona

     10.62960        11.12180  

TRY - Turkish Lira

     17.40880        19.96490  

USD - US Dollar

     1.05300        1.06660  

ZAR - South African Rand

     17.20860        18.0986  

[2.4] Basis of preparation

 

13


[2.4.1] Business combinations and goodwill

Business combinations are recognised using the acquisition method under IFRS 3. To this end, the identifiable assets acquired and the liabilities assumed are recognised at their respective acquisition-date fair value. The consideration transferred in a business combination is the aggregate of the fair value, at the date of exchange, of assets acquired, liabilities assumed and equity instruments issued by the acquirer, in exchange for control of the acquiree.

Goodwill is the positive difference between the consideration transferred, increased by both the fair value at the acquisition date of any non-controlling interests already held in the acquiree and the amount of non-controlling interests held in the acquiree by third parties (measured at fair value or based on the present value of the acquiree’s identifiable net assets), and the fair value of such assets and liabilities.

At the acquisition date, goodwill is allocated to each of the largely independent cash-generating units that are expected to benefit from the synergies of the business combination.

If the difference between the consideration transferred (increased by the above components) and the fair value of the net assets acquired is negative, this is recognised as a gain from a bargain purchase in the income statement in the year of acquisition.

Any goodwill related to non-controlling interests is included in the carrying amount of the relevant equity investments.

After initial recognition, goodwill is not amortised and is recognised net of any cumulative impairment losses, calculated using the methods set out in section [2.4.6] Impairment losses.

As set out in section [3.2] Goodwill of this report, the market multiples method is used to determine the fair value of goodwill, using listed comparable companies (these multiples are compared with the implicit multiple calculated using the group’s actual figures), except for CGU TechMah for which the value in use is defined using estimated future cashflows by applying a discount rate.

IFRS 3 is not applied retrospectively to business combinations that took place prior to 1 January 2018, i.e., the date of the parent’s transition to the IFRS. Accordingly, the amount of goodwill determined under the previous reporting standards, i.e., the carrying amount at such date, is maintained for such business combinations, subject to the recognition of any impairment losses.

[2.4.2] Intangible assets

An intangible asset is an identifiable asset without physical substance, controlled by the group and that generates future economic benefits, in addition to goodwill when acquired against consideration.

Identifiability is defined with reference to the possibility of distinguishing the intangible asset acquired from goodwill. An intangible asset is identifiable when it: (i) arises from a legal or contractual right or (ii) is separable, i.e., can be sold, transferred, licensed, rented, or exchanged, either individually or together with a related contract. An entity controls an asset if it has the power to obtain the future economic benefits flowing from the underlying resource and to restrict the access of others to such benefits.

Intangible assets are stated at cost, which is determined in the same manner as for property, plant and equipment.

Intangible assets with finite useful lives are amortised over their estimated useful lives starting from when they are available for use.

 

14


The amortisation rates adopted in 2022 are shown in the following table by asset category:

 

     2022  

Development expenditure

     5 - 10 years  

Industrial patents and intellectual property rights

     10 - 20 years  

Concessions, licences, trademarks and similar rights

     3 - 4 - 5 years  

Other

     Contract term / maximum 6 years  

Development expenditure

Development expenditure is expensed when incurred.

Development expenditure incurred for a specific project is only capitalised when the group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use and for sale, its intention to complete such asset and use or sell it, how the intangible asset will generate probable future economic benefits, the availability of adequate technical, financial and other resources to complete the development and its ability to measure reliably the expenditure attributable to the intangible asset during its development.

Subsequent to initial recognition, development expenditure is measured at cost less any accumulated amortisation and any accumulated impairment losses. Amortisation of the asset starts from when the development phase has been completed and the asset is available for use. The asset is amortised over the period for which the underlying project is expected to generate revenue for the group.

Industrial patents and intellectual property rights

Industrial patents and intellectual property rights refer to costs for patents owned by Limacorporate S.p.A..

Concessions, licences, trademarks and similar rights

This caption refers to costs to file and register trademarks and costs incurred to acquire commercial licences. The acquisition costs are amortised over a period equal to the useful life of the acquired right.

Other intangible assets

This caption refers to leasehold improvements. The capitalised costs are amortised on the basis of the residual term of the relevant lease contract.

[2.4.3] Property, plant and equipment

Property, plant and equipment are recognised at acquisition or production cost including directly attributable costs incurred to ready the asset for its intended use. Such cost includes costs to replace parts of equipment and plant when they are incurred if they meet the recognition requirements.

Assets acquired under business combinations before 1 January 2018 (the date of the parent’s transition to the IFRS) are recognised at their pre-existing carrying amount, determined within such business combinations in accordance with the previous reporting standards, i.e., at deemed cost.

The carrying amount (cost less accumulated depreciation and cumulative impairment losses) of the replaced parts of equipment and plant is taken to profit or loss at the time of replacement.

Maintenance and repair costs, which do not add to the value of the assets and/or prolong their residual useful lives, are expensed when incurred. Otherwise they are capitalised.

Property, plant and equipment are stated net of any accumulated depreciation and any cumulative impairment losses determined using the methods set out below. Depreciation is calculated on a straight-line basis over the estimated useful life of the asset for the group.

 

15


The depreciation rates used are shown in the following table by asset category:

 

     2022  

Buildings

     3%  

Light constructions

     10%  

General and specific plant

     10% - 15.5%  

Machinery

     15.5%  

Sundry and small equipment

     25%  

Production equipment

     10%  

Office furniture and machines

     12%  

Electronic office machines

     20%  

Transport vehicles

     20%  

Cars

     25%  

Right-of-use assets

     Lease term  

The residual value of the assets, the useful life and the depreciation method applied are reviewed at each year end and adjusted prospectively if necessary.

If significant parts of an item of property, plant and equipment have different useful lives, such parts are recognised separately. Land, free of construction or annexed to buildings, is recognised separately and is not depreciated since it has an unlimited useful life.

The carrying amount of an item of property, plant and equipment and every significant part initially recognised is eliminated on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from the derecognition of the item (calculated as the difference between the carrying amount of the asset and the net disposal proceeds) is included in profit or loss when the item is derecognised.

[2.4.4] Leases

IFRS 16 defines the recognition, measurement, presentation and disclosure requirements for leases. Under IFRS 16, lessees are required to recognise all leases using a single accounting model similar to that used to recognise finance leases under IAS 17.

If a contract contains a lease, at the commencement date, the lessee shall recognise an asset representing its right to use the underlying leased asset and a lease liability representing its obligation to make lease payments. The lessee shall recognise interest on the lease liability and depreciation of the right-of-use asset separately. At inception of a contract, the entity shall assess whether the contract is, or contains, a lease. The contract is, or contains, a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. An entity shall determine the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend the lease if the lessee is reasonably certain to exercise that option and periods covered by an option to terminate the lease if the lessee is reasonably certain not to exercise that option.

[2.4.5] Equity investments

Investments in associates and joint ventures are measured using the equity method, recognising the group’s share of the profits or losses for the year in the income statement, with the exception of the effects related to other changes in the equity of the investee, other than owner transactions, that are directly recognised in other comprehensive income.

In the event of losses exceeding the carrying amount of the equity investment, the excess is recognised in a specific provision to the extent the parent is obliged to fulfil legal or constructive obligations to the investee or to cover its losses.

Investments in other companies are measured at fair value and the fair value gains and losses are taken to equity. If fair value cannot be reliably determined, they are measured at cost, adjusted for any impairment losses.

 

16


[2.4.6] Impairment losses

At the reporting date, the carrying amount of property, plant and equipment, intangible assets, financial assets and equity investments is tested for indicators of impairment. Should such indicators exist, the group estimates the recoverable amount of the asset to check the recoverability of the carrying amount and determine any impairment loss to be recognised. Intangible assets with indefinite useful lives or not yet available for use are tested for impairment at least annually, irrespective of whether any indication of impairment exists, or more frequently if an indication of impairment exists.

In order to identify impairment losses, assets are grouped into the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets (the cash-generating unit, CGU). Reference should be made to section [3.2] Goodwill for details of the group’s CGU. The goodwill generated by business combinations is allocated to the CGU that is expected to benefit from the combinations’ synergies. The recoverable amount of an asset or a CGU is the higher of its value in use and its fair value less costs to sell.

Multiples are compared with the implicit multiple calculated using the group’s actual figures. When the carrying amount of an asset or a CGU exceeds its recoverable amount, the group recognises an impairment loss in profit or loss. Impairment losses on the CGU are allocated first to reduce the carrying amount of any goodwill allocated to it and then to the other assets of the CGU pro rata on the basis of their carrying amounts. Impairment losses on goodwill cannot be reversed. Impairment losses on other assets are reversed to the carrying amount that would have been determined (net of amortisation and depreciation) had no impairment losses been recognised in prior years.

The market multiples method is used to determine the value in use using listed comparable companies for the group’s CGU except for TechMah CGU where the value in use of the CGU Techmah is defined using estimated future cashflows by applying a discount rate (weighted average cost of capital).

[2.4.7] Financial instruments

The financial instruments held by the group are described below.

Financial assets

Financial assets include equity investments, current securities, loans and borrowings, as well as derivatives with a positive fair value, trade receivables and other assets, in addition to cash and cash equivalents.

Specifically, cash and cash equivalents include cash, bank deposits and highly marketable securities that are readily convertible to cash and are subject to an immaterial risk of changes in value.

Current securities include short-term or marketable securities which represent temporary investments of available funds and do not meet the requirements to be classified as cash and cash equivalents. Financial assets represented by debt instruments are classified in the consolidated financial statements as at 31 December 2022 and measured using the business model adopted by the group for managing financial assets and based on the cash flows related to each financial asset. Financial assets also include equity investments not held for trading. Such assets are strategic investments and the group has opted to recognise fair value gains or losses thereon through profit or loss (fair value through profit or loss, FVTPL).

Financial assets are tested for impairment using a model based on expected credit losses.

Financial liabilities

Financial liabilities include loans and borrowings, as well as derivatives with a negative fair value, trade payables and other liabilities.

Financial liabilities are classified and measured at amortised cost, with the exception of those initially measured at fair value, e.g., financial liabilities related to earn-out considerations for business combinations and derivatives and financial liabilities for options on non-controlling interests.

 

17


Derecognition of financial assets and liabilities

A financial asset or liability (or, where applicable, part of a financial asset/liability or part of a group of similar financial assets/liabilities) is derecognised when the group unconditionally transfers the contractual rights to receive the cash flows of the financial asset or the obligation to make payments or fulfil other obligations related to the liability.

[2.4.8] Inventories

Raw materials and packaging are measured at the lower of purchase cost and estimated replacement value based on market trends. The cost is calculated using the weighted average cost for the year.

Semi-finished products and finished goods are measured at purchase or production cost, considering their stage of completion, or their realisable value based on market trends, if lower. The production cost includes the reasonably attributable portion of direct and indirect manufacturing costs.

The resulting amount is written down through the allowance for inventory write-down to account for items whose expected realisable value is lower than their cost.

[2.4.9] Trade receivables and other assets and trade payables and other liabilities

Trade receivables and other assets that derive from the supply of credit facilities, goods or services to third parties are classified under current assets, except when they are due after one year of the reporting date with reference to loans and receivables. If they have a set due date, current and non-current loan assets, other current and non-current assets and trade receivables, with the exception of derivatives, are measured at amortised cost calculated using the effective interest method. If they do not have a set due date, financial assets are measured at cost. Loans and receivables due after one year that are non-interest bearing or accruing interest lower than market rates are discounted using market rates.

The above financial assets are measured using the expected credit loss impairment model introduced by IFRS 9.

Trade payables and other liabilities that arise from the acquisition of credit facilities, goods or services from a third party supplier are classified under current liabilities, except when they are due after one year of the reporting date with reference to loans and borrowings.

On initial recognition, current and non-current loans and borrowings, other current and non-current liabilities and trade payables are stated at fair value, which normally coincides with the transaction price including transaction costs. Subsequently, all financial liabilities are measured at amortised cost calculated using the effective interest method.

[2.4.10] Employee benefits

The liability related to short-term employee benefits paid during the employment relationship is recognised on an accruals basis at the amount accrued at the reporting date.

The liability related to employee benefits paid upon or after termination of the employment relationship via defined benefit plans, is recognised at the amount accrued at the reporting date.

The liability related to employee benefits paid upon or after termination of the employment relationship via defined benefit plans, net of any plan assets and advances granted, is calculated using actuarial assumptions and recognised on an accruals basis in line with the service needed to obtain the benefits. Such liability is calculated by independent actuaries. The gain or loss deriving from the actuarial calculation is fully recognised in the statement of comprehensive income for the relevant year.

Defined benefit plan liabilities are measured using the actuarial assumptions set out in section [3.14] Employee benefits of the notes to the consolidated financial statements as at 31 December 2022.

 

18


[2.4.11] Provisions for risks and charges

The provisions for risks and charges are recognised when the group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the expenditure required to settle the present obligation or transfer it to third parties at the reporting date. Where the effect of the discounting is material, the provisions are calculated by discounting the estimated future cash flows at a rate that reflects current market assessments of the time value of money. When discounting is used, the carrying amount of the provision increases to reflect the passage of time and this increase is recognised as borrowing cost.

[2.4.12] Share-based payments

The grant-date fair value of equity-settled share-based payment arrangements agreed with employees is generally recognised as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognised as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognised is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant-date fair value of the share-based payment is measured to reflect such conditions. With regard to non-vesting conditions, any differences between expected and actual outcomes do not have an impact on the consolidated financial statements as at 31 December 2022.

The fair value of the amount payable to employees in respect of cash-settled share-based payments is recognised as an expense with a corresponding increase in liabilities, over the period during which the employees become unconditionally entitled to payment. The liability is remeasured at each reporting date and at the settlement date based on the fair value of the share-based payments. Any fair value gains or losses are recognised in profit or loss.

The parent has had agreements with some managers for the award of options and/or shares for several years (see section [4.8] Incentive plans).

[2.4.13] Revenue and expense

Based on the five-step model introduced by IFRS 15, the group recognises revenue after identifying the contract(s) with a customer and the performance obligations in the contract (transfer of goods and/or services), determining the transaction price to which it expects to be entitled in exchange for fulfilling performance obligations (at a point in time or over time). Revenue is measured on the basis of the transaction price excluding amounts collected on behalf of third parties. Based on the group’s internal analysis of contracts with customers, the group has not identified any performance obligations that are satisfied over time and, therefore, the group recognises revenue upon the transfer of control of the promised goods or services to the customer. Revenue is measured to the extent that it is probable that the economic benefits will flow to the group and the amount can be measured reliably.

Revenue is adjusted for any discounts and volume rebates allowed by the group in contracts with customers and for the payback (variable considerations) see [3.20] Revenue and other revenue and income and [3.13] Provisions for risks and charges for payback system.

Expense is recognised when the goods and services are sold or consumed during the year or by systematic allocation, or when it is not possible to identify their future use.

Expense items are classified by nature in accordance with the applicable IFRS.

[2.4.14] Government grants

Grants related to income are taken to profit or loss in the year in which the relevant expense is recognised.

 

19


Grants related to assets received for projects and development activities are recognised under liabilities and subsequently recognised under operating revenue in line with the amortisation and depreciation of the relevant assets.

Grants due for investments in research and development are recognised in line with the progress of the research, calculated on the basis of the progress reports issued to the relevant bodies and the stage of completion reported by those in charge of the research, if all requirements for their disbursement are met.

[2.4.15] Financial income and expense

Financial income and expense are recognised on an accruals basis on the basis of interest accrued on the net amount of the relevant financial assets and liabilities, using the effective interest method.

[2.4.16] Dividends

Dividends are recognised when the shareholder’s right to receive payment is established.

[2.4.17] Income taxes

Income taxes recognised in profit or loss are the sum of current and deferred taxes.

Income taxes for the year are determined on the basis of ruling legislation. They are recognised in profit or loss, except for those related to items recognised directly in equity, for which the tax effect is accounted for directly in equity.

Income tax liabilities are recognised under current tax liabilities, net of advances paid. Any tax credits are recognised under current tax assets.

Deferred tax assets and liabilities are calculated on the temporary differences between the carrying amounts of assets and liabilities (resulting from the application of the accounting policies set out in note [2.4] Basis of preparation) and their tax bases (deriving from the application of the tax legislation ruling in the country of the subsidiaries). Current and deferred tax assets and liabilities are offset when the group has the legally enforceable right to offset.

Deferred taxes are calculated using the tax rates expected to be enacted in the years in which the temporary differences will be recovered or settled. Deferred tax assets and liabilities are not discounted.

Deferred tax assets are recognised on temporary differences and to the extent that it is probable the group will have future taxable profits that will allow their recovery.

[2.4.18] Fair value

IFRS 13 is a common framework for fair value measurement and relevant disclosure when this measurement is required or allowed by other IFRS. Specifically, the standard sets out the definition of fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

IFRS 13 establishes a hierarchy that categorises the inputs used in the valuation techniques adopted to measure fair value into different levels, as follows:

 

   

level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity has the ability to access at the measurement date;

 

   

level 2: inputs other than quoted prices included in level 1 that are observable for the assets or liabilities, either directly or indirectly;

 

   

level 3: unobservable inputs for the assets or liabilities.

 

20


In some cases, the inputs used to measure the fair value of an asset or a liability might be categorised within different levels of the fair value hierarchy. In those cases, the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The group recognises transfers among the different levels of the fair value hierarchy at the end of the year in which the transfer took place.

Reference should be made to the notes to the individual financial statements items for the definition of the fair value hierarchy level used to classify the individual instruments measured at fair value or whose fair value is disclosed.

The fair value of derivatives is calculated by discounting estimated cash flows using the market interest rates at the reporting date and the credit default swaps issued by the counterparty and group companies, to include the non-performance risk explicitly provided for under IFRS 13.

Where market prices are not available, the fair value of non-derivative medium/long-term financial instruments is calculated by discounting estimated cash flows using the market interest rates at the reporting date and considering counterparty risk for financial assets and credit risk for financial liabilities.

[2.4.19] Use of estimates

In preparing the consolidated financial statements as at 31 December 2022, the directors were required to apply accounting policies that are, at times, based on judgements or past experience or assumptions deemed reasonable and realistic at the time, depending on the relevant circumstances. The application of such estimates and assumptions impacts the carrying amounts recognised in the statement of financial position, income statement, statement of comprehensive income and statement of cash flows, in addition to the disclosure provided. The end results of the assessments in which such estimates and assumptions were used may differ from those recognised in the consolidated financial statements as at 31 December 2022 due to the inherent uncertainty of the assumptions and the conditions underlying the estimates.

Actual results may differ from those estimated. Estimates and assumptions are reviewed on an ongoing basis. The effect of a change in accounting estimates is recognised in profit or loss in the period of the change, if the change affects that period only, or the period of the change and future periods, if the change affects both.

Estimates mainly refer to the following captions:

 

   

Impairment losses on non-current assets and goodwill;

 

   

loss allowance;

 

   

allowance for inventory write-down;

 

   

recoverability of deferred tax assets;

 

   

estimate of the provisions for risks and contingent liabilities;

 

   

financial liabilities;

 

   

employee incentive plans.

Impairment losses on non-current assets and goodwill

Non-current assets include property, plant and equipment, intangible assets including goodwill and other financial assets.

Management periodically revises the carrying amount of non-current assets held and used and assets held for sale when events and circumstances require such revision. This is performed using the estimates of cash flows the group expects to derive from using or selling the asset and suitable discount rates for calculating the present value.

When the carrying amount of a non-current asset has been impaired, the group recognises an impairment loss equal to the excess between the carrying amount and the amount to be recovered through use or sale of the asset, determined using the parent’s or group’s most recent plans. Reference should be made to note [2.4.6] Impairment losses.

 

21


Loss allowance

The loss allowance is management’s best estimate of the potential credit losses on trade receivables from end customers. Reference should be made to note [2.4.8] Trade receivables and other assets and trade payables and other liabilities for a description of the criteria used in estimating the allowance.

Allowance for inventory write-down

Inventories of slow-moving raw materials and finished goods are periodically analysed on the basis of historical data and the possibility of selling them at prices lower than normal market transactions. If, as a result, the carrying amount of inventories needs to be written down, the group recognises a specific allowance for inventory write-down.

Recoverability of deferred tax assets

The group pays taxes in numerous countries and some estimates are required to calculate the taxes in each jurisdiction. It recognises deferred tax assets to the extent that it is probable that future taxable profits will be available and over a period of time compatible with the time horizon implicit in the management estimates.

Estimate of the provisions for risks and contingent liabilities

The group could be subject to legal and tax disputes regarding a vast range of issues that are subject to the jurisdiction of various countries. Disputes and litigation against the group are subject to a different degree of uncertainty, including the facts and circumstances inherent to each dispute, the jurisdiction and different applicable laws. In the ordinary course of business, management consults its legal consultants and legal and tax experts. The group recognises a liability for such disputes when it is deemed probable that they will result in an outflow of resources and when the amount of the resulting losses can be reasonably estimated. If an outflow of resources is possible but the amount cannot be determined, such fact is disclosed in the notes to the consolidated financial statements as at 31 December 2022.

Employee incentive plans and financial liabilities

Reference is made to section [4.8] Incentive plans for a description of the calculation of the fair value of share-based payments as part of group management incentive plans. Section [3.15] Current and non-current financial liabilities provides details of the calculation of fair value of the group’s financial liabilities.

[2.4.20] Translation of foreign currency items

The financial statements of each consolidated company are prepared using the functional currency related to the economy where each company operates. Transactions in currencies other than the functional currency are recognised at the exchange rate at the date of the transaction. Foreign currency monetary assets and liabilities are subsequently translated at the closing rate and any exchange differences are taken to profit or loss. Foreign currency non-monetary assets and liabilities recognised at historical cost are translated using the exchange rate at the date of the transaction.

For consolidation purposes, the foreign currency reporting packages of consolidated companies are translated using the closing rates for asset and liability captions, including goodwill and consolidation adjustments, and the average rate for the year (if similar to the respective transaction-date rates) or the period under consolidation, if lower, for income statement captions. The relevant exchange differences are taken directly to the statement of comprehensive income and reclassified to profit or loss when control over the investee is lost and, thus, it is deconsolidated.

[2.4.21] Operating segments

An operating segment is a component of an entity:

 

   

that engages in business activities from which it may earn revenue and incur expenses (including revenue and expenses relating to transactions with other components of the same entity);

 

   

whose operating results are regularly reviewed by the entity’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and

 

   

for which discrete financial information is available.

 

22


Note [4.2] Operating segments provides information about the single operating segment identified.

[2.4.22] New standards and interpretations, revisions and amendments to existing standards

As required by IAS 8 Accounting policies, changes in accounting estimates and errors, below are the new standards and interpretations, in addition to amendments to existing and applicable standards and interpretations, applicable starting from 1 January 2022 and not yet in effect at the reporting date.

[2.4.22.1] New standards and interpretations applicable from 1 January 2022

The amendments to the IFRS adopted during the year included:

On 14 May 2020, the IASB published the following amendments:

 

   

Amendments to IFRS 3 Business combinations: which update the reference in IFRS 3 to the revised conceptual framework without significantly changing its requirements.

 

   

Amendments to IAS 16 Property, plant and equipment: which prohibit deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced during the testing of such item. An entity recognises the proceeds from selling such items, and the cost of producing those items, in profit or loss.

 

   

Amendments to IAS 37 Provisions, contingent liabilities and contingent assets: which specify that the cost of fulfilling a contract comprises the costs that relate directly to the contract. Costs that relate directly to a contract can either be incremental costs of fulfilling that contract (e.g., direct labour, materials) or an allocation of other costs that relate directly to fulfilling contracts (e.g., the allocation of the depreciation charge for an item of property, plant and equipment used in fulfilling the contract).

 

   

Annual Improvements 2018-2020: which amend IFRS 1 First-time adoption of International Financial Reporting Standards, IFRS 9 Financial instruments, IAS 41 Agriculture and the illustrative examples of IFRS 16 Leases.

All of the amendments are effective for annual periods beginning on or after 1 January 2022.

The adoption of the other standards and interpretations detailed above has not had a material impact on the measurement of the group’s asset, liabilities, costs and revenue.

[2.4.22.2] Standards, amendments and interpretations not yet mandatory and not adopted early at 31 December 2022

On 18 May 2017, the IASB published IFRS 17 Insurance contracts which will replace IFRS 4 Insurance contracts.

The objective of the new standard is to ensure that an entity provides relevant information that faithfully represents the rights and obligations deriving from insurance contracts issued. The IASB developed the standard to eliminate inconsistencies and deficiencies in existing accounting standards, providing a single principle-based framework covering all types of insurance contracts, including reinsurance contracts held by an insurance company.

The new standard also sets out presentation and disclosure requirements to improve the comparability between entities operating in the insurance industry.

Under IFRS 17, an entity measures an insurance contract using a general accounting model or a simplified version called the premium allocation approach.

The main features of the general model are:

 

   

estimates and assumptions of future cash flows are always current;

 

   

measurement reflects the time value of money;

 

23


   

estimates make maximum use of observable market data;

 

   

there is a current and explicit measurement of risk;

 

   

expected profit is deferred and aggregated in groups of insurance contracts at initial recognition; and

 

   

expected profit is recognised over the coverage period after adjustments from changes in the cash flows assumptions related to each group of contracts.

Under the premium allocation approach, an entity measures the liability for the remaining coverage of a group of insurance contracts on the condition that, at initial recognition, the entity reasonably expects that this will be an approximation of the general model. Contracts with a coverage period of one year or less are automatically eligible for PAA. The simplifications arising from PAA do not apply to the measurement of the liability for incurred claims, measured under the general model. However, there is no need to discount those cash flows if the balance is expected to be paid or received in one year or less from the date the claims are incurred.

An entity shall apply the new standard to issued insurance contracts, including reinsurance contracts issued, reinsurance contracts held and also to investment contracts with a discretionary participation feature (DPF).

The standard is effective for annual periods beginning on or after 1 January 2023. Early application is permitted only for entities that apply IFRS 9 Financial instruments and IFRS 15 Revenue from contracts with customers.

The directors do not expect the adoption of this standard to have a significant effect on the group’s consolidated financial statements as at 31 December 2022.

On 9 December 2021, the IASB published “Amendments to IFRS 17 Insurance contracts: Initial application of IFRS 17 and IFRS 9 – Comparative information”. The amendment is a transition option relating to comparative information about financial assets presented on initial application of IFRS 17. The amendment is aimed at helping entities to avoid temporary accounting mismatches between financial assets and insurance contract liabilities, and therefore improve the usefulness of comparative information for users of financial statements. IFRS 17 incorporating the amendment is effective for annual reporting periods beginning on or after 1 January 2023.

On 12 February 2021, the IASB published “Disclosure of accounting policies—Amendments to IAS 1 and IFRS Practice statement 2” and “Definition of accounting estimates—Amendments to IAS 8”. These amendments will help companies improve accounting policy disclosures so that they provide more useful information to investors and other primary users of the financial statements and distinguish changes in accounting estimates from changes in accounting policies. The amendments are effective for annual reporting periods beginning on or after 1 January 2023 and early adoption is permitted.

On 7 May 2021, the IASB published “Amendments to IAS 12 Income taxes: Deferred tax related to assets and liabilities arising from a single transaction” which clarify how companies account for deferred tax on transactions such as leases and decommissioning obligations. The amendments are effective for annual reporting periods beginning on or after 1 January 2023 and early adoption is permitted.

Limacorporate S.p.A. did not opt for early adoption of these standards.

Other standards, amendments and interpretations

 

   

On 23 January 2020, the IASB published “Amendments to IAS 1 Presentation of financial statements: classification of liabilities as current or non-current” and, on 31 October 2022, “Amendments to IAS 1 Presentation of financial statements: non-current liabilities with covenants which clarify how an entity classifies debt and other financial liabilities as current or non-current. The amendments are effective for annual reporting periods beginning on or after 1 January 2024 and early adoption is permitted.

 

   

On 22 September 2022, the IASB published “Amendments to IFRS 16 Leases: lease liability in a sale and leaseback” which requires a seller-lessee to measure lease liabilities arising from a sale and leaseback in a way that it does not recognise any amount of the gain or loss that relates to the right of use it retains. The amendments are effective for annual reporting periods beginning on or after 1 January 2024 and early adoption is permitted.

 

24


   

On 30 January 2014, the IASB published IFRS 14 Regulatory deferral accounts permits a first-time adopter of IFRS Standards to continue to recognise its rate regulation activities in accordance with its previous GAAP. As the parent and group are not a first-time adopter, this standard is not applicable.

The group will adopt such new standards and amendments, on the basis of the relevant application date, and will assess the potential impacts on the consolidated financial statements as at 31 December 2022 when they are endorsed by IASB.

 

25


[3] Notes to the consolidated financial statements as at 31 December 2022

Below are comments on the statement of financial position captions as at 31 December 2022. For details on statement of financial position captions deriving from related party transactions, reference should be made to note [4.6] Related party transactions.

[3.1] Other intangible assets

Other intangible assets at 31 December 2022 amount to €58,234 thousand, up €4,639 thousand on the previous year end (€53,595 thousand). Changes in other intangible assets in 2021 and 2022 and a breakdown of historical cost, accumulated amortisation and any cumulative impairment losses are summarised in the following tables.

 

(€‘000)

                                                
     01/01/2021      Exchange
difference
     Increases      Reclassifications      Decreases      Amortisation      31/12/2021  

Development expenditure

     664        1,414        7,322        28,340        0        -3,858        33,882  

Industrial patents and intellectual property rights

     1,181        0        413        924        0        -455        2,063  

Concessions, licences, trademarks and similar rights

     5,016        10        2,411        1,722        0        -2,914        6,245  

Assets under development and payments on account

     37,267        1,041        3,893        -30,987        -38        0        11,176  

Other

     349        2        53        1        -9        -167        229  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     44,477        2,467        14,092        0        -47        -7,394        53,595  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(€‘000)

                                                
     31/12/2021      Exchange
difference
     Increases      Reclassifications      Decreases      Amortisation      31/12/2022  

Development expenditure

     33,882        2,057        5,132        943        0        -4,896        37,118  

Industrial patents and intellectual property rights

     2,063        0        485        0        0        -339        2,208  

Concessions, licences, trademarks and similar rights

     6,245        51        2,322        446        0        -3,165        5,900  

Assets under development and payments on account

     11,176        19        3,911        -1,646        -953        0        12,507  

Other

     229        2        271        257        -2        -257        500  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     53,595        2,129        12,121        0        -955        -8,657        58,234  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

€‘000

      
     01/01/2021  
     Historical cost      Accumulated amortisation      Carrying amount  

Development expenditure

     1,639        975        664  

Industrial patents and intellectual property rights

     2,984        1,802        1,181  

Concessions, licences, trademarks and similar rights

     18,905        13,889        5,016  

Assets under development and payments on account

     37,267        —         37,267  

Other

     1,207        859        348  
  

 

 

    

 

 

    

 

 

 

Total

     62,002        17,525        44,477  
  

 

 

    

 

 

    

 

 

 

 

€‘000

      
     31/12/2021  
     Historical cost      Accumulated amortisation      Carrying amount  

Development expenditure

     38,593        4,711        33,882  

Industrial patents and intellectual property rights

     3,904        1,841        2,063  

Concessions, licences, trademarks and similar rights

     21,272        15,027        6,245  

Assets under development and payments on account

     11,176        0        11,176  

Other

     1,246        1,017        229  
  

 

 

    

 

 

    

 

 

 

Total

     76,191        22,596        53,595  
  

 

 

    

 

 

    

 

 

 

 

26


€‘000

      
     31/12/2022  
     Historical cost      Accumulated amortisation      Carrying amount  

Development expenditure

     46,425        9,307        37,118  

Industrial patents and intellectual property rights

     3,663        1,455        2,208  

Concessions, licences, trademarks and similar rights

     22,359        16,458        5,901  

Assets under development and payments on account

     12,507        0        12,507  

Other

     1,731        1,231        500  
  

 

 

    

 

 

    

 

 

 

Total

     86,685        28,451        58,234  
  

 

 

    

 

 

    

 

 

 

Intangible assets with an indefinite useful life only comprise goodwill, while the other assets (development expenditure, industrial patents and intellectual property, concessions, licences, trademarks and similar rights, other intangible assets and assets under development and payments on account) all have a finite life. More information on each item is provided below.

Development expenditure, amounting to €37,118 thousand, comprises:

 

   

€1,060 thousand incurred by the parent mainly related to Physica and Hybrid Glenoid;

 

   

€14,424 thousand related to the allocation of part of the goodwill arising on consolidation transferred at the acquisition date for TechMah Medical LLC (resulting from a step acquisition achieved in stages but consolidated at 100% as per the anticipated acquisition method). Such goodwill was partly allocated to development expenditure and partly to goodwill. The relevant estimated useful life is ten years;

 

   

€1,382 thousand for the recognition of the additional new milestone agreed with the sellers of such company in June 2020 via an addendum to the initial agreement, for the development of an additional implant technology to those agreed at the acquisition;

 

   

€20,252 thousand related to costs capitalised by TechMah Medical LLC for the development of its products which will enrich the group’s portfolio with digital solutions designed to assist surgeons with operations. The same applies as for the second point regarding amortisation.

The significant increase on the previous year end is due to the costs incurred by TechMah Medical LLC in 2022 to develop products. The recoverability of TechMah costs is supported by the result of the discounted cash flow method applied to test the TechMah CGU; based on the impairment test exercise at 31 December 2022 the VIU is lower than the carrying amount of the CGU so, as provided for IAS 36, management fully impaired firstly the goodwill. The carrying amount of the CGU after the impairment of goodwill is recoverable by the VIU defined.

In summer 2023 the Management of Limacorporate took the strategic decision to stop the Spart Space project (TechMah business). All digital activities and resources have been refocused on other projects (please refer to Events after the reporting date paragraph).

Amortisation of this caption amounts to €4,896 thousand.

Industrial patents and intellectual property rights, amounting to €2,208 thousand, are comprised of costs incurred by Limacorporate S.p.A. to acquire patents in 2022 and previous years.

Concessions, licences, trademarks and similar rights of €5,900 thousand are comprised of costs incurred by:

 

   

the parent (€2,861 thousand) for costs to register Lima products on the European, US, Chinese, Korean and Japanese markets;

 

   

other group companies (€448 thousand) for costs mainly to register products on the Brazilian market;

 

   

the parent (€2,336 thousand) for costs incurred to purchase commercial licences (€1,146 thousand), software programs (€1,086 thousand) and to register trademarks (€104 thousand);

 

   

other group companies (€255 thousand).

Amortisation of this caption amounts to €3,165 thousand.

 

27


Assets under development and payments on account, amounting to €12,507 thousand, is comprised of the following:

 

   

€12,107 thousand for costs incurred by Limacorporate S.p.A. for development activities, payments on account for software licences, costs to register the Lima products and costs incurred to acquire patents;

 

   

€400 thousand related to other group companies.

“Other”, amounting to €500 thousand, refers to the following companies for leasehold improvements:

 

   

Limacorporate S.p.A. for €19 thousand;

 

   

Lima USA for €269 thousand;

 

   

Lima Orthopaedics Australia for €23 thousand;

 

   

Lima Implantes for €56 thousand;

 

   

Lima Korea for €115 thousand;

 

   

other group companies for €18 thousand.

The capitalised costs are amortised over the residual term of the relevant lease contract and amortisation of this caption amounts to €257 thousand.

Total amortisation of intangible assets taken to profit or loss amounts to €8,657 thousand.

[3.2] Goodwill

Goodwill amounts to €384,216 thousand.

Pursuant to IAS 36, goodwill is not subject to amortisation, but is tested for impairment at least annually or more frequently if events or circumstances indicate that it might be impaired. With regard to testing goodwill for impairment, the group identified two CGUs for its operations,-one for the Group except TechMah (“Group CGU”) and one related to TechMah . It considered the sources of information set out by IAS 36 such as the fact that management monitors the group’s performance and takes strategic decisions about its product offering and investments at group level, except for TechMah business which is a separate CGU.

The goodwill recognised in the consolidated financial statements as at 31 December 2022 in relation to the above-mentioned merger, together with other items of goodwill, was tested for impairment at the reporting date. Specifically, the recoverable amount of the group’s assets was calculated by estimating their fair value and comparing it with the carrying amount of consolidated net invested capital at 31 December 2022 in order to examine whether recognised amounts had been impaired.

The market multiples method is used to determine the fair value of goodwill of the Group CGU, using listed comparable companies. These multiples are compared with the implicit multiple calculated using the group’s actual figures. The market multiples analysis based on companies operating in sectors comparable to those of Limacorporate (performed on the date the impairment test was carried out on seven comparable companies) provides supporting evidence about the carrying amount of goodwill recognised in the 2022 consolidated financial statements as at 31 December 2022. This is because the market multiples (which show an average enterprise value of between 15 and 17 times gross operating profit) are higher and/or in line with the multiple obtained by comparing the group’s actual net invested capital at the end of 2022 (i.e., including goodwill) to consolidated gross operating profit.

As a result of such checks, based on market references (i.e., market multiples) compared with the group’s implicit multiple, no impairment indicators have been detected to date for goodwill allocated to the Group CGU.

The group separately measured TechMah Medical LLC’s business related to the Smart SPACE digital solution.

The recoverable value of the TechMah CGU was determined as its value in use, on the basis of the cashflows discounted using a rate that reflects the risk conditions (WACC of 13.5%). The recoverable amount determined with aforementioned method led to the full impairment of goodwill (€ 15,109 thousand) allocated to the CGU.

 

28


[3.3] Property, plant and equipment

Property, plant and equipment and other assets amount to €79,837 thousand, down €1,936 thousand compared to 31 December 2021 (€81,773 thousand).

Changes in property, plant and equipment in 2021 and 2022 and a breakdown of historical cost, accumulated depreciation and any cumulative impairment losses are summarised in the following tables:

 

     01/01/2021      Exchange
difference
     Increases      Decreases      Depreciation      Reclassifications      Other
changes
     31/12/2021  

Land and buildings

     15,907        0        508        0        -703        34        0        15,746  

Leased land and buildings

     9,364        377        827        -78        -2,539        0        -880        7,071  

Plant and equipment

     17,945        14        1,753        -754        -4,282        343        0        15,019  

Leased plant and equipment

     26        0        0        0        -15        0        2        13  

Industrial and commercial equipment

     35,489        670        15,676        -626        -14,967        578        0        36,820  

Leased industrial and commercial equipment

     15        0        935        0        -315        0        0        635  

Other assets

     1,605        35        643        -22        -576        0        0        1,683  

Other leased assets

     2,695        7        1,221        0        -1,726        0        -52        2,145  

Assets under construction and payments on account

     2,244        81        1,349        -78        0        -955        0        2,641  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     85,288        1,184        22,912        -1,558        -25,123        0        -930        81,773  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     31/12/2021      Exchange
difference
     Increases      Reclassifications      Decreases      Other
changes
     Depreciation      31/12/2022  

Land and buildings

     15,746        0        456        35        -67        0        -674        15,496  

Leased land and buildings

     7,071        226        2,087        0        -5        623        -3,247        6,755  

Plant and equipment

     15,019        0        3,601        2,255        -17        0        -4,442        16,416  

Leased plant and equipment

     13        0        82        0        0        0        -16        79  

Industrial and commercial equipment

     36,820        258        14,647        -63        -1,156        0        -15,832        34,674  

Leased industrial and commercial equipment

     635        0        0        0        0        -58        -558        19  

Other assets

     1,683        15        706        3        -20        0        -600        1,787  

Other leased assets

     2,145        2        1,577        0        0        90        -1,514        2,299  

Assets under construction and payments on account

     2,641        64        1,991        -2,231        -154        0        0        2,311  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     81,773        566        25,145        0        -1,418        655        -26,884        79,837  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     01/01/2021  
     Historical cost      Accumulated
depreciation
     Accumulated
impairment losses
     Carrying amount  

Land and buildings

     24,082        7,610        565        15,907  

Leased land and buildings

     18,471        9,107        —         9,364  

Plant and equipment

     53,382        35,437        —         17,945  

Leased plant and equipment

     117        91        —         26  

Industrial and commercial equipment

     116,513        80,857        167        35,489  

Leased industrial and commercial equipment

     30        15        —         15  

Other assets

     6,727        5,122        —         1,605  

Other leased assets

     6,176        3,481        —         2,695  

Assets under construction and payments on account

     2,244        —         —         2,244  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     227,741        141,720        733        85,288  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     31/12/2021  
     Historical cost      Accumulated
depreciation
     Accumulated
impairment losses
     Carrying amount  

Land and buildings

     24,624        8,313        565        15,746  

Leased land and buildings

     17,344        10,273        0        7,071  

Plant and equipment

     54,318        39,299        0        15,019  

Leased plant and equipment

     119        106        0        13  

Industrial and commercial equipment

     132,183        95,196        167        36,820  

Leased industrial and commercial equipment

     966        331        0        635  

Other assets

     7,257        5,574        0        1,683  

Other leased assets

     6,016        3,871        0        2,145  

Assets under construction and payments on account

     2,641        0        0        2,641  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     245,468        162,963        733        81,773  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

29


     31/12/2022  
     Historical cost      Accumulated
depreciation
     Accumulated
impairment losses
     Carrying amount  

Land and buildings

     23,870        8,374        0        15,496  

Leased land and buildings

     19,868        13,113        0        6,755  

Plant and equipment

     59,135        42,719        0        16,416  

Leased plant and equipment

     202        122        0        80  

Industrial and commercial equipment

     141,939        107,009        256        34,674  

Leased industrial and commercial equipment

     66        47        0        19  

Other assets

     7,937        6,150        0        1,787  

Other leased assets

     5,069        2,770        0        2,299  

Assets under construction and payments on account

     2,311        0        0        2,311  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     260,397        180,304        256        79,837  
  

 

 

    

 

 

    

 

 

    

 

 

 

The €456 thousand increase in land and buildings during the year is chiefly due to costs incurred by the parent to build the new electrical substation at the Villanova production facility and to acquire land to extend the production facility.

The increase in plant and machinery mainly refers to the construction of plant for the new electrical substation, the completion of the new packaging line and investments made to purchase production machinery, specifically additive manufacturing machines.

Industrial and commercial equipment amounts to €34,674 thousand and is chiefly comprised of surgical instruments capitalised during the current and previous years.

Other assets include office furniture and machines, electronic office machines, transport vehicles and cars. Investments, amounting to €706 thousand, refer to purchases of electronic office machines and furniture.

The €1,991 thousand increase in assets under construction and payments on account during the year is chiefly due to costs incurred to expand the Villanova production facility and for the purchase of production equipment and machinery.

Some plant and machinery are subject to a special lien at the reporting dates. Additional information is provided in note [3.15] Current and non-current financial liabilities.

Changes in right-of-use assets deriving from the application of IFRS 16 are set out in the following tables, where such changes are shown for each asset category along with details on the historical cost and accumulated depreciation:

 

     01/01/2021      Exchange
difference
     Increases      Decreases      Depreciation      Other
changes
     31/12/2021  

Right-of-use assets

                    

Leased land and buildings

     9,364        377        827        -78        -880        -2,539        7,071  

Leased plant and equipment

     26        0        0        0        2        -15        13  

Leased industrial and commercial equipment

     15        0        935        0        0        -315        635  

Other leased assets

     2,695        7        1,221        0        -52        -1,726        2,145  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     12,100        384        2,983        -78        -930        -4,595        9,864  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     31/12/2021      Exchange
difference
     Increases      Decreases      Depreciation      Other
changes
     31/12/2022  

Right-of-use assets

                    

Leased land and buildings

     7,071        226        2,087        -5        623        -3,247        6,755  

Leased plant and equipment

     13        0        82        0        0        -16        79  

Leased industrial and commercial equipment

     635        0        0        0        -58        -558        19  

Other leased assets

     2,145        2        1,577        0        90        -1,514        2,300  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     9,864        228        3,746        -5        655        -5,335        9,153  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Lease liabilities deriving from the application of IFRS 16 are included under current and non-current financial liabilities (analysed in note [3.15] Current and non-current financial liabilities). Changes in current and non-current lease liabilities from 1 January 2021 to 31 December 2022 are set out below:

 

30


     01/01/2021      Increases      Decreases      Reclassifications      31/12/2021  

Lease liabilities as per IFRS 16 - non-current portion

     6,573        1,369        0        -3,518        4,423  

Lease liabilities as per IFRS 16 - current portion

     3,384        0        -3,384        3,518        3,518  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     9,957        1,369        -3,384        0        7,941  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     01/01/2022      Exchange
difference
     Increases      Decreases      Other
changes
     Reclassifications      31/12/2022  

Lease liabilities as per IFRS 16 - non-current portion

     4,423        83        3,663        0        655        -4,273        4,552  

Lease liabilities as per IFRS 16 - current portion

     3,518        -7        40        -4,559        0        4,273        3,265  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     7,941        76        3,703        -4,559        655        0        7,817  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

[3.4] Equity investments

Equity investments amount to €2 thousand at 31 December 2022.

The following information is provided on direct and indirect equity investments in subsidiaries, associates and other companies.

Subsidiaries

All of the subsidiaries are included in the consolidation scope.

Other companies

Equity investments in other companies amount to €2 thousand and refer to CAAF Interregionale dipendenti S.r.l., Consorzio Friuli Energia, Terra degli Elimi and CE.R.ME.T..

[3.5] Deferred tax assets and liabilities

Deferred tax assets and liabilities are only offset when this is legally provided for within the same tax jurisdiction. The group recognised deferred tax assets and liabilities on the temporary differences between carrying amounts and tax bases. The latter were calculated using the rates ruling when the temporary differences will reverse in the different countries where the group operates.

Deferred tax assets and liabilities are broken down as follows at 31 December 2022 and 2021:

 

     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Deferred tax assets

     11,558        11,947        12,758        -390        -811  

Deferred tax assets arising on consolidation

     20,151        21,515        19,137        -1,364        2,378  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     31,709        33,462        31,895        -1,754        1,567  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Deferred tax liabilities

     9,414        7,931        5,461        1,483        2,470  

Deferred tax liabilities arising on consolidation

     9,861        9,364        7,525        497        1,839  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     19,275        17,295        12,986        1,980        4,309  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Reference should be made to section [3.29] of these notes for more details on deferred tax assets and liabilities and the differences that generated them.

The recoverability of DTA accrued at 31 December 2022 was based on the business plan prepared by the management which shows the recoverability considering the future taxable incomes.

 

31


[3.6] Other non-current assets

Other non-current assets, amounting to €861 thousand, mainly refer to guarantee deposits for lease contracts taken out by the group and prepayments (€162 thousand), mostly for insurance and maintenance.

[3.7] Inventories

A breakdown of inventories at 31 December 2022 and 2021 is provided below:

 

     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Raw materials and supplies

     6,272        6,094        6,106        178        -12  

Work in progress and semi-finished products

     11,533        12,861        14,344        -1,328        -1,483  

Contract work in progress

     0        0        0        0        0  

Finished goods

     79,583        77,993        74,875        1,590        3,118  

Payments on account

     0        0        0        0        0  

Goods in transit

     831        647        177        184        470  

Allowance for inventory write-down

     -11,492        -10,174        -11,336        -1,318        1,162  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     86,728        87,421        84,166        -693        3,255  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Inventories were measured using the cost of the production company for the consolidated companies.

The allowance for inventory write-down, amounting to €11,492 thousand at 31 December 2022, changed as follows during the year:

 

Balance at 01/01/2021

     11,336  

Exchange difference

     74  

Utilisations

     -1,952  

Accruals

     716  
  

 

 

 

Balance at 31/12/2021

     10,174  
  

 

 

 

Exchange difference

     54  

Utilisations

     -1,883  

Accruals

     3,146  
  

 

 

 

Balance at 31/12/2022

     11,491  
  

 

 

 

Utilisations of the allowance refer to the scrapping of obsolete goods by Limacorporate S.p.A. and subsidiaries during the year.

[3.8] Trade receivables

Trade receivables at 31 December 2022 amount to €70,161 thousand, compared to €66,891 thousand at the previous year end, and are broken down as follows:

 

     Gross amount      Loss allowance      Carrying amount
31/12/2021
 

Trade receivables - third parties

     68,971        2,082        66,889  

Trade receivables - related parties

     2        —         2  
  

 

 

    

 

 

    

 

 

 

Total

     68,973        2,082        66,891  
  

 

 

    

 

 

    

 

 

 

 

     Gross amount      Loss allowance      Carrying amount
31/12/2022
 

Trade receivables - third parties

     72,527        2,387        70,140  

Trade receivables - related parties

     21        —         21  
  

 

 

    

 

 

    

 

 

 

Total

     72,548        2,387        70,161  
  

 

 

    

 

 

    

 

 

 

 

32


Trade receivables originate from group activities and are broken down by geographical segment as follows:

 

     Total Italy
31/12/2021
     Total EU
31/12/2021
     Rest of world
31/12/2021
     Total
31/12/2021
 

Trade receivables

     21,642        20,938        24,309        66,889  

From subsidiaries

     0        0        2        2  

From associates

     0        0        0        0  

From parents

     0        0        0        0  

From subsidiaries of parents

     0        0        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     21,642        20,938        24,311        66,891  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     Total Italy      Total EU      Rest of world      Total  
     31/12/2022      31/12/2022      31/12/2022      31/12/2022  

Trade receivables

     23,021        20,681        26,438        70,140  

From subsidiaries

     0        0        0        0  

From associates

     0        0        0        0  

From parents

     0        21        0        21  

From subsidiaries of parents

     0        0        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     23,021        20,702        26,438        70,161  
  

 

 

    

 

 

    

 

 

    

 

 

 

Trade receivables in foreign currency are detailed in section [4.2] Financial instruments – Fair value and risk management under Other information, to which reference should be made.

The loss allowance amounts to €2,387 thousand at 31 December 2022 (31 December 2021: €2,082 thousand).

The loss allowance is management’s estimate of the expected credit losses on trade receivables from customers. The estimate is based on the group’s expected credit losses, determined using past experience with similar receivables, current and historical overdue amounts, losses and collections, a careful monitoring of credit quality and forecasts of economic and market conditions.

Changes in the loss allowance in 2022 and 2021 are as follows:

 

     2022      2021  

Opening balance

     2,082        1,940  

Exchange difference

     33        10  

Accruals

     519        544  

Utilisations

     -247        -412  
  

 

 

    

 

 

 

Closing balance

     2,387        2,082  
  

 

 

    

 

 

 

Specifically:

 

     Receivables
impaired
individually
     Receivables
impaired
collectively
     Total  

01/01/2021

     1,660        280        1,940  

Utilisations

     -398        -14        -412  

Accruals

     406        138        544  

Exchange difference

     11        0        11  
  

 

 

    

 

 

    

 

 

 

31/12/2021

     1,679        403        2,082  
  

 

 

    

 

 

    

 

 

 

Utilisations

     -230        -17        -247  

Accruals

     324        195        519  

Exchange difference

     -10        43        33  
  

 

 

    

 

 

    

 

 

 

31/12/2022

     1,763        624        2,387  
  

 

 

    

 

 

    

 

 

 

 

33


A breakdown of the loss allowance by past due category is as follows:

 

     Not yet due      Overdue      Total  
            <30 days      30 - 90 days      90 - 180 days      Over 180 days         

Gross trade receivables at 01 January 2021

     38,238        6,112        5,375        4,306        10,968        64,998  

Loss allowance

     0        0        0        64        1,876        1,940  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net trade receivables at 01 January 2021

     38,238        6,112        5,375        4,242        9,092        63,058  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Gross trade receivables at 31 December 2021

     41,111        6,422        5,362        4,622        11,454        68,971  

Loss allowance

     0        0        0        24        2,059        2,082  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net trade receivables at 31 December 2021

     41,111        6,422        5,362        4,598        9,396        66,889  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Gross trade receivables at 31 December 2022

     47,181        7,324        6,108        4,519        7,394        72,526  

Loss allowance

     0        0        1        1        2,385        2,387  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net trade receivables at 31 December 2022

     47,181        7,324        6,109        4,520        9,779        74,913  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

[3.9] Current tax assets

Tax assets at 31 December 2022 amount to €2,087 thousand and include direct taxes, particularly in relation to the parent’s IRES and IRAP for €1,619 thousand.

[3.10] Other current assets

Other current assets at 31 December 2022 amount to €14,192 thousand, compared to €11,247 thousand at the previous year end, and are broken down as follows:

 

     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Grants

     5,281        4,976        4,807        305        169  

Other tax assets

     827        758        1,024        69        -266  

Advances to agents

     776        779        964        -3        -185  

VAT

     1,317        1,340        923        -23        417  

Advances to suppliers

     1,327        939        804        388        135  

Hire and maintenance

     873        657        669        216        -12  

Other sundry

     1,354        420        489        934        -69  

VAT to be offset

     325        118        461        207        -343  

Insurance premiums and sureties

     574        507        396        67        111  

Other

     676        239        349        437        -110  

VAT claimed for reimbursement

     289        289        289        0        0  

Other tax credit

     0        0        104        0        -104  

Rent

     32        112        88        -80        24  

Deductible taxes

     0        50        50        -50        0  

Social security institutions

     20        20        21        0        -1  

IRAP-IRES reimbursement

     18        18        18        0        0  

Tax withholdings

     2        8        7        -6        1  

Factoring interest

     40        10        3        30        7  

Accrued income

     3        3        3        0        0  

Tax assets - interest

     454        0        0        454        0  

Leasing fees

     0        0        0        0        0  

IRPEF reimbursement

     4        5        0        -1        5  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     14,192        11,248        11,469        2,944        -221  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Grants chiefly refer to the amount accrued by the parent (€5,281 thousand) and are broken down as follows:

 

   

SIB grant (€4,630 thousand);

 

   

MCBEES grant (€258 thousand);

 

   

AIM grant (€40 thousand);

 

   

IAREPAM grant (€158 thousand;

 

   

PROST3SIS grant (€195 thousand).

 

34


Other assets also include guarantee deposits on gas and electricity consumption (€472 thousand).

[3.11] Cash and cash equivalents

Cash and cash equivalents at 31 December 2022 amount to €25,920 thousand, compared to €21,503 thousand at the previous year end. This caption shows the group’s liquidity at the reporting date.

Reference should be made to the statement of cash flows for an analysis of changes in cash and cash equivalents.

 

     31/12/2022      31/12/2021      31/12/2020      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Bank and postal accounts

     25,903        21,486        26,257        4,417        -4,771  

Cash-in-hand and cash equivalents

     17        17        16        0        1  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     25,920        21,503        26,273        4,417        -4,770  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

[3.12] Equity

Equity attributable to the owners of the parent amounts to €306,564 thousand, and is broken down as follows:

 

(€‘000)

                                  
     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Share capital

     9,868        9,868        9,868        0        0  

Share premium reserve

     14,425        14,425        14,425        0        0  

Legal reserve

     2,101        2,101        2,101        0        0  

Equity injections

     28,051        28,051        23,088        0        4,963  

Merge reserve

     288,261        288,261        288,261        0        0  

Actuarial reserve

     31        -23        -25        54        2  

Translation reserve

     2,379        1,508        -334        871        1,842  

Other reserves

     2,687        -2,329        -2,329        5,016        0  

Retained earnings (losses carried forward)

     -21,966        -18,862        -6,380        -3,104        -12,482  

Profit (loss) for the year

     -19,273        -2,539        -12,482        -16,735        9,943  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Equity

     306,564        320,463        316,194        -13,899        4,269  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

The share capital at 31 December 2022 is €9,868 thousand and is fully subscribed and paid up. It is comprised of 9,989,718 ordinary shares without a nominal amount. It is unchanged on the previous year end.

The share premium reserve amounts to €14,425 thousand and is unchanged on the previous year end.

The legal reserve amounts to €2,101 thousand. This reserve is not distributable and did not change during the year.

Negative goodwill, amounting to €288,261 thousand, comprises the effects of the reverse merger between the parent and Emil Holding III S.p.A. in October 2016 on equity.

Capital injections for capital increase, amounting to €28,051 thousand, comprise the contribution in kind made in 2021 by the shareholder for the acquisition of TechMah Medical (€4,963 thousand), the capital injection made by the shareholder in June 2020 (€20,000 thousand) and the effects of a contribution in kind made in 2019 by the shareholder in relation to the transaction carried out by the subsidiary Lima USA with Hospital for Special Surgery (HSS) (€3,088 thousand).

The contribution in kind made by the shareholder in 2021 is directly related to the shared-based payment of certain milestones regarding the acquisition of TechMah Medical. Under the agreement signed in 2018, the subsidiary Lima USA would allocate the founding shareholders of TechMah Medical a set number of new EmilNewCo Sarl (indirect parent of Limacorporate S.p.A. with a 100% interest) shares upon reaching set targets regarding the development of new products benefiting the group.

 

35


The above-mentioned allocation of shares in October 2021 led to a share capital increase for EmilNewCo and the recognition of an amount due from the founding shareholders of TechMah Medical equal to the liability recognised by Lima USA for the contractual milestones to be settled. The two transactions between the founding shareholders of Techmah Medical and Lima Group (EmilNewCo Sarl, Limacorporate S.p.A. and Lima USA) were offset using claim notes, which generated the capital injection referred to above.

With a similar transaction, the collaboration agreement signed with HSS in January 2019 for the production of implants within the hospital led to the following agreements:

 

   

a six-year lease for the premises where Lima USA will produce the implants for HSS, of which payment for the first three years has been made by awarding HSS a fixed number of new EmilNewCo Sarl shares and the second three years will be paid by monthly instalments;

 

   

a clause which establishes that HSS will bear an agreed amount of the cost of any leasehold improvements made by Lima USA and will receive an agreed number of new EmilNewCo Sarl shares in return.

The above-mentioned allocation of shares led to a share capital increase for EmilNewCo and the recognition of an amount due from HSS. The prepaid lease instalments and the set amount related to the leasehold improvements generated a liability for Lima USA towards HSS. The two transactions between HSS and Lima Group (EmilNewCo, Limacorporate S.p.A. and Lima USA) have been offset using claim notes, which generated the capital injection referred to above.

Other reserves also include:

 

   

the revaluation reserve, which arose from the merger of Lima S.p.A., amounts to €111 thousand and is recognised in compliance with Law no. 413 of 30 December 1991 in relation to deferred tax on the revalued amount of land and industrial buildings. There were no changes in the reserve during the year;

 

   

the reserve deriving from the application of IAS 19 Employee benefits amounting to €31 thousand;

 

   

the IFRS 2 reserve amounting to €4,650 thousand deriving from the accounting treatment of cash-settled share-based payment and equity-settled share-based payment arrangements;

 

   

the reserve for unrealised exchange rate gains of €1,764 thousand, comprising the net unrealised gains on the allocation of the parent’s profit for the previous year;

 

   

the translation reserve, with a positive balance of €2,379 thousand, reflects the changes in the group’s share of the equity of consolidated companies due to changes in exchange rates of such companies’ functional currencies compared to the presentation currency of the consolidated financial statements as at 31 December 2022.

The correction of error on payback for €6.945 thousand has been recorded on retained earnings / losses carried forward (see section “Transition to IFRS issued by IASB”).

The following table provides information on the possibility of use and distribution of each of the parent’s equity items, along with their utilisations in the last three years:

 

36


Description

   Amount      Possibility
of use
     Available
portion
     Utilisation in the
previous three
years to cover
losses
     Utilisation in the
previous three
years for other
reasons
 

Share capital

     9,868        B           

Share premium reserve

     14,425        A, B        14,425        

Legal reserve

     2,101        B        2,101        

Capital injections for capital increase

     28,051        A, B, C        28,051        9,215     

Merge reserve

     288,261        A, B, C        288,288        246     

Actuarial reserve

     31              

Translation reserve

     2,379              

Other reserves

     2,687              

Retained earnings (losses carried forward)

     -21,966           10,770        
  

 

 

       

 

 

    

 

 

    

 

 

 

TOTAL

     325,838           343,635        9,461        0  
  

 

 

       

 

 

    

 

 

    

 

 

 

Non-Distributable Portion (Legal Reserve)

           2,101        

Non-Distributable Portion (Reserve For Unrealised Exchange Rate Gains)

           1,199        

Capitalised Start-Up And Development Costs)

           14,387        
        

 

 

       

Residual Distributable Amount

           325,949        
        

 

 

       

 

*

A: for capital increases; B: to cover losses; C: dividends

The following supplementary information is provided on the parent’s reserves:

1) Reserves or other provisions that do not contribute to the taxable profit of shareholders in the event of distribution regardless of when they are formed.

 

     31/12/2022      31/12/2021      01/01/2021  

Emil Holding III merger reserve

     288,261        288,261        288,261  

Capital injections for capital increase

     28,051        28,051        23,088  

Share premium reserve

     14,425        14,425        14,425  
  

 

 

    

 

 

    

 

 

 

Total

     330,737        330,737        325,774  
  

 

 

    

 

 

    

 

 

 

2) Reserves or other provisions that do contribute to the taxable profit of the parent in the event of distribution regardless of when they are formed.

 

     31/12/2022      31/12/2021      01/01/2021  

Revaluation reserve as per Law no. 413/1991

     111        111        111  

Reserve as per article 55 of Presidential decree no. 917/86

     —         —         —   
  

 

 

    

 

 

    

 

 

 

Total

     111        111        111  
  

 

 

    

 

 

    

 

 

 

3) Reserves included in share capital.

Reserves or other provisions that contribute to the taxable profit of shareholders in the event of distribution, irrespective of when they were set up, for a free share capital increase by using the reserve as per the shareholders’ resolution of 15 October 1999.

 

     31/12/2022      31/12/2021      01/01/2021  

Extraordinary reserve

     540        540        540  
  

 

 

    

 

 

    

 

 

 

Total

     540        540        540  
  

 

 

    

 

 

    

 

 

 

[3.13] Provisions for risks and charges

Details of this caption and changes therein during 2021 and 2022 are provided below:

 

37


(€‘000)

                                         
     01/01/2021      Exchange
differences
     Increases      Decreases      Reclassification      31/12/2021  

Pension and similar provisions

     889        0        198        -162        0        925  

Other provisions

     11,958        -4        4,226        -1,222        -569        14,389  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     12,847        -4        4,424        -1,384        -569        15,314  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

(€‘000)

                                         
     01/01/2022      Exchange
differences
     Increases      Decreases      Reclassification      31/12/2022  

Pension and similar provisions

     925        0        236        -576        0        585  

Other provisions

     14,389        14        4,166        -1,997        0        16,571  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     15,314        14        4,402        -2,573        0        17,156  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Agents’ termination indemnity (€585 thousand) is the estimated liability deriving from the application of ruling legislation and the contractual clauses in relation to the termination of agency contracts. Unlike accruals to the provision for risks, guarantees and other provisions, accruals to agents’ termination indemnity are classified by nature among costs for services. The decreases of the year refer to utilisations of the provision following the termination of agency contracts and the release of the provision when not due.

Other provisions, amounting to €16,571 thousand, are comprised as follows:

 

   

the provision for charges of €1,859 thousand, of which €1,460 thousand related to commission expense on revenue yet to be invoiced; and €399 thousand related to highly probable non-competition agreements the payment date of which is not yet known;

 

   

the provision related to the payback system for €14.3 million;

 

   

compensation for damage caused by products of €300 thousand;

 

   

other disputes/contingent liabilities of €95 thousand.

The decreases of the year mainly refer to the release of a provision following the signing of a settlement agreement with an agent.

The accruals of the year mainly refer to the best estimate of the amounts due under the payback system.

The market in which the Group operates is strictly controlled by laws and regulations such as, e.g., the EU Medical Devices Regulation (‘MDR’) in Europe and the Federal Food, Drug and Cosmetic Act (‘FDCA’) in USA. In order to demonstrate adherence to regulatory requirements and to maintain the ability to sell its products, the Group must obtain and maintain authorisations and certifications from the relevant authorities. Discussions are currently underway with the Australian authority, the Therapeutic Goods Administration (the ‘TGA’), which has been provided with clarification regarding an observation made by the TGA on the high revision rate of certain elements of the ‘SMR’ shoulder solution.

[3.14] Employee benefits

Employee benefits chiefly refer to post-employment benefits recognised by the parent. These are defined benefit plans in accordance with IAS 19. Changes in the caption during the two years were as follows:

 

38


     31/12/2022      31/12/2021      Variation  

Balance at 1 January

     1,442        1,421        21  

Exchange difference

     -13        0        -13  

Benefits settled/advances paid

     -189        -123        -66  

Accruals

     1,716        1,651        65  

Cometa Fund, other pension funds

     -1,599        -1,376        -223  

Post-employment benefits - Substitute tax on revaluation

     0        -132        132  

Interest

     10        4        6  

Actuarial gain

     -71        -3        -68  
  

 

 

    

 

 

    

 

 

 

TOTAL

     1,296        1,442        -146  
  

 

 

    

 

 

    

 

 

 

The main actuarial assumptions used in determining the present value of post-employment benefits are set out below:

 

    

31/12/2022

  

31/12/2021

Actual mortality rate    RG48 tables determined by the State general accountant    RG48 tables determined by the State general accountant
Actual invalidity rate    INPS disability/invalidity tables    INPS disability/invalidity tables

Rate of early terminations (dismissals and resignations)

   Constant annual average rate of 5%    Constant annual average rate of 5%

Rate of requests for advances of post-employment benefits

  

- Constant annual average rate of 3%

 

- Average amount of 70% of post-employment benefits accrued

  

- Constant annual average rate of 3%

 

- Average amount of 70% of post-employment benefits accrued

Annual technical discount rate    3.6% - iBoxx index Eur Corporate AA 10    1% - iBoxx index Eur Corporate AA 10+
Annual future inflation rate    2.50%    1.50%
Pension dates    In line with ruling legislation    In line with ruling legislation
Annual increase in post-employment benefits    Fixed rate of 3.38% plus 75% of the inflation rate noted by ISTAT for December of the previous year    Fixed rate of 2.63% plus 75% of the inflation rate noted by ISTAT for December of the previous year

The occurrence of reasonably possible changes in the actuarial assumptions at 31 December 2022 and 2021 would have impacted the defined benefit obligations by the amounts shown below:

 

2021 sensitivity analysis

 
(€‘000)    Defined benefit obligation  
     +      -  

Annual discount rate (+/- 0.50%)

     959        999  

Annual inflation rate (+/- 0.25%)

     991        967  

Annual turnover rate (+/- 2.00%)

     978        979  

2022 sensitivity analysis

 
(€‘000)    Defined benefit obligation  
     +      -  

Annual discount rate (+/- 0.50%)

     890        922  

Annual inflation rate (+/- 0.25%)

     915        896  

Annual turnover rate (+/- 2.00%)

     907        906  

The number of employees by category at the reporting date and the average for the year is set out below:

 

39


Workforce

   31/12/2020      Incoming      Outgoing      Other
changes
     Reclassifications      31/12/2021      2021 average  

Blue collars

     227        11        -18        0        0        220        224  

White collars

     589        108        -104        -1        -1        591        590  

Junior managers

     90        7        -9        0        -12        76        83  

Managers

     32        5        -9        0        13        41        37  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     938        131        -140        -1        0        928        933  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

Workforce

   31/12/2021      Incoming      Outgoing      Other
changes
     Reclassifications      31/12/2022      2022 average  

Blue collars

     220        22        -14        -20        -4        204        212  

White collars

     591        140        -132        1        -2        598        595  

Junior managers

     76        8        -14        15        5        90        83  

Managers

     41        4        -9        4        1        41        41  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     928        174        -169        0        0        933        931  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

[3.15] Current and non-current financial liabilities

Non-current financial liabilities, amounting to €10,165 thousand at 31 December 2022, comprise the portion of loans and borrowings due after one year and are broken down as follows:

 

     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Non-current bank loans and borrowings

     363        746        1,379        -383        -633  

Non-current bank loans and borrowings (due after five years)

     2        0        41        2        -41  

Bonds

     0        272,556        271,136        -272,556        1,420  

Other financial liabilities

     5,248        5,848        8,279        -600        -2,431  

Lease liabilities as per IFRS 16

     4,552        4,423        6,573        129        -2,150  

Derivatives

     0        0        0        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     10,165        283,573        287,407        -273,408        -3,834  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Current financial liabilities, amounting to €336,659 thousand, comprise the current portion of loans and borrowings and are broken down as follows:

 

     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Credit cards

     383        47,000        40,000        -46,617        7,000  

Advances on exports

     0        7,771        14,817        -7,771        -7,046  

Current bank loans and borrowings

     54,000        3,518        3,384        50,482        134  

Non-current bank loans and borrowings

     386        1,346        1,318        -960        28  

Bonds - current portion

     274,039        882        909        273,157        -27  

Accrued expenses on bonds - due within one year

     1,979        0        0        1,979        0  

Accrued financial expense - due within one year

     298        401        405        -103        -4  

Loans and borrowings with other financial backers

     2,310        280        211        2,030        69  

Lease liabilities as per IFRS 16

     3,265        338        112        2,927        226  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     336,659        61,536        61,156        275,123        380  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Current financial liabilities chiefly include the bonds issued by Limacorporate S.p.A. in 2017 equal to €274,039 thousand at the reporting date. They are senior secured bonds redeemable in 2023 for a total nominal amount of €275 million. The bonds were initially recognised at fair value, net of directly related costs, and measured at amortised cost applying the effective interest rate method.

 

40


The bonds have coupons based on the 3-month Euribor plus a 3.75% spread, with a Euribor floor threshold of 0.00%. They are listed on the Euro MTF market of the Luxembourg Stock Exchange and the professional section of the ExtraMOT market of the Italian Stock Exchange.

The coupons mature every three months on 15 February, 15 May, 15 August and 15 November each year starting from 15 November 2017.

The following guarantees were issued in relation to the bonds:

 

   

pledge on the shares of Limacorporate S.p.A.;

 

   

pledge on the shares of some subsidiaries;

 

   

pledge on some of the current accounts of the parent and some subsidiaries;

 

   

special lien on plant, machinery and other items of property, plant and equipment of the parent;

 

   

lien on certain categories of assets of some subsidiaries;

 

   

guarantees on some categories of assets of the parent and some subsidiaries.

In relation to the refinancing put in place in 2017, as well as the issue of bonds, Limacorporate also finalised an agreement for a new super senior revolving credit facility for a maximum of €60 million. It may also be used partially, in several instalments with set repayment terms. If the financial covenants are complied with, the interest rate is the same as the bonds, i.e., 3-month Euribor plus a 3.75% spread, with a Euribor floor threshold of 0.00%.

The same guarantees provided for the issue of the bonds were granted for this revolving credit facility; specifically:

 

   

pledge on the shares of Limacorporate S.p.A.;

 

   

pledge on the shares of some subsidiaries;

 

   

pledge on some of the current accounts of the parent and some subsidiaries;

 

   

special lien on plant, machinery and other items of property, plant and equipment of the parent;

 

   

lien on certain categories of assets of some subsidiaries;

 

   

guarantees on some categories of assets of the parent and some subsidiaries.

At the reporting date, €54 million of the revolving facility was used (31 December 2021: €47 million).

If more than 35% of the available amount of the revolving facility is used (i.e., draw-downs exceeding €21 million), a covenant related to the ratio of super senior net debt (the amount drawn down from the revolving facility net of liquid funds) to consolidated gross operating profit (as defined in the loan agreement), which cannot exceed 1.83, is activated under the terms of the contract. Such covenant was complied with at 31 December 2022.

On 3 February 2023, the parent issued new senior secured bonds redeemable in February 2028 for a total nominal amount of €295 million. In addition to the bond issue, the parent also signed a new super senior revolving facility for a maximum of €65 million expiring in November 2027.

On 9 March 2023, the parent privately placed additional notes with the same terms and conditions as the bonds, for an amount of €15 million.

The pre-existing bonds and super senior revolving facility were fully redeemed and repaid.

The bonds have coupons based on the 3-month Euribor plus a 5.75% spread, with a Euribor floor threshold of 0.00%. They are listed on the Euro MTF market of the Luxembourg Stock Exchange.

The completion of the refinancing also saw a significant capital injection of €46,295 thousand by the parent’s shareholder.

The management, after having carefully assessed, and positively considered, the effects of the actions in progress have the reasonable expectation that the Company may continue to operate in the foreseeable future, consequently the management have prepared the financial statements as at 31 December 2022 on a going concern basis.

Non-current financial liabilities include loans and borrowings from other financial backers (€185 thousand) related to the amount due in 2024 for the acquisition of a business unit from the group’s Sicilian distributor.

 

41


On 25 September 2017, the parent entered into an agreement with the agency MT Ortho to acquire its business unit comprising the components organised for the marketing, sale and after-sales assistance of Lima medical devices in Sicily and Calabria. Specifically, the business unit included:

 

   

ongoing supply contracts with the healthcare facilities;

 

   

supply contracts under negotiation;

 

   

goodwill.

The consideration of €3.7 million was to be paid as follows:

 

   

€740 thousand when the contract was signed;

 

   

€2,960 thousand in six annual instalments (from 2018 to 2023), the payment of which depends on whether a certain level of sales is maintained in the region until the payment is complete.

The agreement was renegotiated in late 2020, accelerating the payment of the remaining 2021 instalments of €1,645 thousand against a €20 thousand decrease in the liability and the renegotiation of the commissions in the area.

Loans and borrowings from other financial backers also include amounts yet to be paid in relation to the acquisition of TechMah Medical LLC (contingent consideration). The difference on the previous year end is taken to profit or loss under financial income.

The caption also includes the non-current portion of the medium/long-term loans taken out by the parent for the SICAT and IAREPAM projects and by some branches in relation to the relief available for the Covid-19 pandemic, detailed as follows:

 

Description

   Company      Original
amount
    

Rate

   Expiry
date
     Residual
amount at
01/01/2021
     Guarantee  

SICAT sustainable growth fund 1st progress report

     Limacorporate S.p.A.        274      Fixed      30/06/2026        190        None  

SICAT sustainable growth fund 2nd progress report

     Limacorporate S.p.A.        339      Fixed      30/06/2026        251        None  

Covid-19 subsidised loan

     Lima France        500      Fixed      31/05/2024        500       
Government
guarantee
 
 

Covid-19 subsidised loan

     Lima Austria        200     

0% until August 2022,

then a floating loan

     31/12/2024        200        None  

Covid-19 subsidised loan

     Lima Switzerland        407      Fixed      31/03/2025        407        None  
     

 

 

          

 

 

    

Total

        1,720              1,548     
     

 

 

          

 

 

    

Description

   Company      Original
amount
    

Rate

   Expiry
date
     Residual
amount at
31/12/2021
     Guarantee  

SICAT sustainable growth fund 1st progress report

     Limacorporate S.p.A.        274      Fixed      30/06/2026        156        None  

SICAT sustainable growth fund 2nd progress report

     Limacorporate S.p.A.        339      Fixed      30/06/2026        206        None  

Covid-19 subsidised loan

     Lima France        500      Fixed      31/05/2024        512       
Government
guarantee
 
 

Covid-19 subsidised loan

     Lima Austria        200     

0% until August 2022,

then a floating loan

     31/12/2024        150        None